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ABSTRACT 
GAOYANG LIANG: Improve induced pluripotent stem cell generation  
by manipulating epigenetic statuses 
(Under the direction of Dr. Yi Zhang) 
Reprogramming of somatic cells to a pluripotent state can be achieved by 
introduction of defined transcription factors. The derived induced pluripotent stem (iPS) 
cells have molecular profiles and developmental potentials similar to embryonic stem (ES) 
cells. However, this reprogramming process is inefficient and its underlying mechanisms 
are poorly understood. To improve the efficiency of iPS cell generation and shed light on 
its mechanisms, I aimed to identify epigenetic modulations that can enhance iPS cell 
generation. By studying chemicals modulating epigenetic status and ES-cell enriched 
epigenetic factors, I demonstrate that butyrate, a histone deacetylase (HDAC) inhibitor, 
and Kdm2b, a histone demethylase specific for H3 lysine 36 dimethylation (H3K36me2) 
are capable of facilitating iPS cell generation. Butyrate not only enhances the efficiency 
of iPS cell generation, but also suppresses the formation of partially reprogrammed cells 
and transformed cells. The enhancing effect of butyrate on reprogramming appears to 
depend on c-Myc and occurs early in reprogramming. Genome-wide microarray analysis 
shows that a set of ES cell-enriched genes are upregulated upon butyrate treatment. 
Kdm2b promotes iPS cell generation via its demethylase and DNA binding activities. 
The Kdm2b-mediated effect on reprogramming is independent of its role in suppressing 
senescence. Kdm2b functions at the beginning of reprogramming and enhances activation 
of early responsive genes in reprogramming. Kdm2b regulates gene activation by directly 
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binding to and demethylating its target loci. Collectively, the research in this dissertation 
show that iPS cell generation can be improved by manipulating epigenetic statuses, 
highlighting the importance of epigenetic modifications in the establishment of 
pluripotency.  
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CHAPTER 1 INTRODUCTION 
 
1.1 Epigenetics 
During development of higher eukaryotes, a single totipotent zygote gives rise to 
all different cell types in the organism. Nearly all the cell types share the same genetic 
content, the genomic DNA, with the totipotent zygote, despite their distinct phenotypes 
and gene expression patterns. This indicates that genetic code per se is insufficient for 
explaining the developmental changes. How such heritable changes occur is the subject 
of epigenetics. 
The term “epigenetics” was first coined by Conrad Waddington as “the branch of 
biology which studies the causal interactions between gene and their products, which 
bring the phenotype into being” (Waddington 1942). As our understanding of biology 
evolves, epigenetics is more specifically defined as the study of heritable changes in 
molecular or cellular phenotype that occurs without alternation in DNA sequence 
(Goldberg et al. 2007). Research over the past decades began to reveal the molecular 
mechanisms contributing to the kaleidoscopic epigenetic phenomena. These mechanisms 
appear to converge on the modulation of chromatin, the complex of DNA and its 
associated proteins and RNAs in nucleus (Bernstein et al. 2007; Martin and Zhang 2007).  
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1.2 Molecular basics for epigenetic regulations 
In eukaryotic cells, DNA is highly condensed and packaged as chromatin in 
nucleus. The basic building unit of chromatin is nucleosome, in which 147 base pairs of 
DNA are wrapped around a histone octamer containing two H2A-H2B dimers and one 
(H3-H4)2 tetramer (Luger et al. 1997; Kornberg and Lorch 1999). Nucleosomes are 
further assembled into higher-order structures, known as chromatin fibers, which in turn 
constitute a large-scale configuration known as chromosome (Woodcock 2006; 
Tremethick 2007). Biological processes based on DNA, such as transcription, replication 
and repair, must cope with the natural barrier posed by the hierarchical organization of 
chromatin (Misteli 2007). Chromatin regulation by covalent modifications of DNA and 
histones, incorporation of variant histones, nucleosome remodeling and noncoding RNAs 
play important roles in establishing chromatin structure and regulating DNA-based 
processes. These regulation strategies ultimately contribute to cellular epigenetic 
landscape. 
DNA methylation and CpG islands 
In vertebrates, genomic DNA is predominantly methylated at cytosine in the 
context of CpG dinucleotides with the exception of regions called CpG islands (Suzuki 
and Bird 2008; Deaton and Bird 2011). DNA methylation is de novo established by DNA 
methyltransferases (DNMTs) 3a and 3b, and maintained through replication by DNMT1, 
which preferentially acts on hemi-methylated DNA (Goll and Bestor 2005; Klose and 
Bird 2006). Deficiency in the DNA methylation machinery leads to early lethality, 
suggesting an essential role of DNA methylation in development (Li et al. 1992; Okano 
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et al. 1999). DNA methylation traditionally correlates with transcription repression. DNA 
methylation has been shown to fortify silencing on  imprinted gene loci (Edwards and 
Ferguson-Smith 2007) and inactivated X chromosome (Payer and Lee 2008). 
Mechanistically, cytosine methylation may suppress gene expression by directly 
inhibiting the binding of transcription factors to DNA; alternatively, methylation can 
recruits methyl-binding domain (MBD) containing transcription corepressor complexes, 
which is capable of modifying chromatin and enforcing repression (Klose and Bird 2006).  
Although once thought as a static epigenetic mark, DNA methylation is subjected 
to dynamic regulation. Methylation can not only be passively diluted in mitosis when 
Dnmt1 is inhibited or absent, but also be actively remove by repair-based mechanisms 
and oxidative conversion (Wu and Zhang 2010). Although the functional significance of 
various demethylation pathways remain to be explored, preliminary evidences suggest 
that oxidative conversion by Tet proteins likely maintain the methylation-free status on 
CpG islands, which is a cohort for transcription regulation (Ficz et al. 2011; Wu et al. 
2011a; Wu et al. 2011b). 
CpG islands (CGIs) are GC-rich, CpG-rich genomic DNA stretches with the 
length of approximate 1000 base pairs. Compared to average genomic DNA, CGIs lack 
DNA methylation and their unmethylated state largely persists throughout development 
(Suzuki and Bird 2008; Deaton and Bird 2011). Most CGIs encompass transcription 
initiation sites and functionally act as promoter, indicating a role in transcription 
regulation for these regions (Illingworth et al. 2010). Despite their unmethylated state, 
genes under the control of CGI promoters do not show correlation with gene expression 
(Suzuki and Bird 2008). However, CGI promoters show permissive signs for 
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transcription, as RNA polymerase II is readily detected on CGI promoters (Guenther et al. 
2007; Hargreaves et al. 2009) and their local chromatin structure displays features of 
active transcription, including destabilized nucleosomes (Ramirez-Carrozzi et al. 2009) 
and enriched histone H3 lysine 4 trimethylation (H3K4me3) (Thomson et al. 2010). 
Silencing of CGI promoters by de novo DNA methylation and/or polycomb-mediated 
H3K27me3 has been thought to be important for epigenetic regulation in development 
(Fouse et al. 2008; Ku et al. 2008; Meissner et al. 2008; Mohn et al. 2008). It has been 
envisioned that, CpG island provides a specialized platform for coordinating transcription 
regulatory machinery. Molecular events occurring on this platform directly influence the 
cellular epigenetic landscape. (Blackledge and Klose 2011; Deaton and Bird 2011).  
Histone modifications 
In addition to DNA, core histones are subjected to covalent modifications. Each 
core histone consists of a globular histone fold domain and a protruding unstructured N-
terminal “tail” (Luger et al. 1997; Kornberg and Lorch 1999). Post-translational 
modifications, such as acetylation, methylation, phosphorylation and ubiquitylation, 
occur predominantly in the tail region at specific residues. Most histone modifications 
have been shown to be reversible, and their physiological levels are balanced by enzymes 
establishing and removing the modifications. Histone modifications function either in 
mediating the establishment of specialized chromatin environments or coordinating with 
other factors in DNA-involved processes (Kouzarides 2007).  
Currently, there are two proposed mechanisms for the functionality of histone 
modifications (Goldberg et al. 2007; Kouzarides 2007). First, modified histones can 
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influence the higher-order structure of chromatin (Tremethick 2007; Henikoff and 
Shilatifard 2011). Histone acetylation seems to facilitate transcription activation in this 
manner. The acetyl moiety neutralizes the positive charge of lysine residues, weakening 
DNA-histone interaction and thereby rendering chromatin an “open” structure (Shogren-
Knaak et al. 2006). Second, histone modifications could recruit specific binding proteins 
that mediate downstream functions. Individual or combinational modifications have been 
hypothesized to serve as a functional “code” in establishing the specialized chromatin 
structure and mediating chromatin-related processes (Strahl and Allis 2000). For instance, 
it has been shown that H3K9me3, a modification enriched in heterochromatin, recruits 
HP1 protein via its chromodomain, which stabilizes the formation of heterochromatin 
(Lachner et al. 2001; Nakayama et al. 2001). H3K27me3, a repressive mark, is bound by 
Pc, a chromodomain-containing subunit of the PRC1 complex, which further carries out 
histone H2A ubiquitylation and reinforce repression (Cao et al. 2002; Fischle et al. 2003). 
H3K4me3, an active mark, specifically interacts with the PHD domain-containing protein 
in the NURF chromatin-remodeling complex, thereby tethering the remodeling activity to 
local chromatin and facilitating gene expression (Li et al. 2006; Wysocka et al. 2006).  
Histone variants 
The majority of nucleosomes are composed of canonical core histones, whose 
syntheses are tightly coupled to DNA replication. In contrast, non-canonical histone 
variants are constitutively expressed throughout cell cycle. These variants with unique 
amino acid compositions and modifications have specialized function in regulating 
chromatin structure and facilitating DNA-based processes (Banaszynski et al. 2010; 
Talbert and Henikoff 2010). For example, CENP-A, centromere-specific H3 
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preferentially binds to AT-rich DNA (as in centromere) with its specialized N-terminal 
tail, and its incorporation into nucleosome leads to atypical DNA bending, and affects 
nucleosome configuration. Such a specialized property is essential for the integrity of 
kinetochore (Black and Bassett 2008). H3.3 and H2A.Z, two variants with slight amino 
acid alterations from core histones, appear to have dual functions. Both H3.3 and H2A.Z 
associate with transcription activation in euchromatin; meanwhile, they localizes in 
pericentromeric regions and/or inactivated X chromosome (Marques et al. 2010; Szenker 
et al. 2011). MacroH2A, an H2A variant with a large C-terminal extension of non-histone 
domain, also plays a role gene suppression in inactivated X chromosome (Gamble and 
Kraus 2010). H2A.X, particularly in its phosphorylated form γH2A.X, is specialized for 
signaling the recruitment of DNA repair machinery and nucleosome remodeling 
complexes upon double strand break (van Attikum and Gasser 2009). In addition, 
deposition of these variants to the chromatin requires specific histone chaperones. 
Interestingly, many histone variants and their deposition are dynamically regulated 
during embryogenesis. Depletions of these variants or chaperones lead embryonic 
lethality, suggesting essential roles of variant histones in development (Banaszynski et al. 
2010). 
Chromatin remodeling  
Nucleosome positioning in the genome is dynamically regulated by ATP-
dependent chromatin remodelers. Chromatin remodelers, which eject and reposition 
nucleosomes, are able to modulate local chromatin structure and control the accessibility 
of DNA to protein factors (Saha et al. 2006; Cairns 2009). These remodelers usually exist 
as large complexes. Based on their ATPase subunits, they can be divided into 4 families 
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based −− SWI/SNF, ISWI, CHD and INO80. The assembly of chromatin remodeling 
complex can be diversified by selective incorporation of non-ATPase subunits (Wu et al. 
2009; Ho and Crabtree 2010). For example, the BAF complexes of the SWI/SNF family 
have different assemblies along differentiation, due to the differential expression patterns 
of subunits. The incorporation of different subunits leads to the specialized functions in 
different differentiation stages (Lessard et al. 2007; Yan et al. 2008; Ho et al. 2009). 
Therefore, precise coordination of chromatin remodeling activities contributes to the 
cellular epigenetic status.  
Noncoding RNA 
In eukaryotic cells, most of the genome is transcribed, resulting in a large number 
of noncoding RNAs (ncRNAs). Some of these molecules have been shown to modulate 
chromatin dynamic and function in epigenetic regulation (Mercer et al. 2009; Wilusz et al. 
2009). A well-known example is Xist and Tsix, two noncoding transcripts involved in X 
chromosome inactivation. Xist initiates silencing by binding to the X chromosome 
inactivation center (Xic) on one of the X chromosomes. Silencing is further reinforced by 
repressive histone modifications, such as H3K9me3 and H3K27me3. On the other hand, 
Tsix is responsible for keeping the active X chromosome from silencing. Tsix can titrate 
the histone modifying enzymes, or deplete Xist by annealing and triggering its 
degradation via RNA interference (RNAi) pathway (Heard and Disteche 2006; Yang and 
Kuroda 2007; Mercer et al. 2009). Furthermore, ncRNAs have also been shown to 
function in enforcing gene silencing in heterochromatin by coupling to RNA processing 
pathways. (Bernstein and Allis 2005; Zaratiegui et al. 2007). In addition, ncRNAs 
directly regulates transcription by other mechanisms: transcription from upstream ncRNA 
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promoter can interfere with the assembly of transcription machinery at the downstream 
promoters; ncRNAs transcribed by proximal promoters can recruit RNA-binding proteins 
that regulate transcription activity of the target promoter; and ncRNAs can serve as a 
cofactor stimulating transcription of adjacent promoter (Mercer et al. 2009; Wilusz et al. 
2009).  
To summarize, epigenetic regulations can be carried out with a variety of 
molecular mechanisms. How these mechanisms are involved in cell type specification 
and cell fate transition requires case-specific investigation.  
1.3 Genetic and epigenetic regulation of embryonic stem cells 
Mammalian development begins when two gamates, sperm and egg, are fused 
into a zygote. Zygote subsequently divides by cleavage into blastomeres. Both the zygote 
and early blastomeres are deemed as totipotent cells for their capacity to generate the 
whole organism; however, they lack the ability to self-renew. As development proceeds, 
cleavage division ends and cells acquire normal cell cycle properties in the blastocyst 
stage. Concurrent with that, first lineage specification takes place, as an outer layer of 
trophoblast and an inner cell mass (ICM) are formed. Trophoblast develops into 
extraembryonic tissues, including placenta, while ICM gives rise to the embryo proper. 
Cells from ICM are deemed as pluripotent cells for their capacity to differentiate into all 
adult cell types. These cells can acquire self-renewal property in specific culture 
conditions in vitro. The derived embryonic stem (ES) cells can be propagated indefinitely 
while maintaining their differentiation potentials. Molecular studies on ES cells show that 
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their unique property is controlled by a specific transcription factor circuitry that 
intertwines with epigenetic regulators.  
Transcription factor circuitry for pluripotency 
Transcription factors activate or repress gene transcription by recognizing their 
target DNA sequences. Oct4, Sox2 and Nanog are considered the core transcription 
factors governing the pluripotent state of ES cells (Jaenisch and Young 2008; Young 
2011). Oct4 and Nanog are specifically enriched in ES cells compared to somatic cells 
(Nichols et al. 1998; Chambers et al. 2003; Mitsui et al. 2003). Oct4 is crucial for 
establishing pluripotency in ICM and ES cells (Nichols et al. 1998; Niwa et al. 2000), 
while Nanog is required for robust maintenance of pluripotency in ES cells and proper 
development after ICM is formed (Mitsui et al. 2003; Chambers et al. 2007; Silva et al. 
2009). Sox2 heterodimerizes with Oct4 and functionally contributes to pluripotency 
(Ambrosetti et al. 2000; Avilion et al. 2003; Masui et al. 2007). The core transcription 
factor triad colocalize with each other to regulate a set of gene loci in ES cells (Boyer et 
al. 2005; Loh et al. 2006; Chen et al. 2008). First, these loci include the promoters of 
these core factors. The self-regulatory positive feedback loop sustains the robust 
expression of these core factors in ES cells. Second, Oct4, Sox2 and Nanog cooperate to 
activate genes expressed in ES cells. More than 60% of active genes in ES cells are target 
of these factors (Young 2011). Third, paradoxically, these core factors also localize to a 
set of lineage-specific genes, whose expression is repressed or “poised” in ES cells but 
rapidly activated upon differentiation. On these loci, these core factors cooperate with 
epigenetic factors, such as Polycomb complexes and SetDB1, which enforce the 
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repression (Boyer et al. 2006; Lee et al. 2006; Bilodeau et al. 2009). It has been thought 
that such a mechanism is crucial for maintaining the undifferentiated state of ES cells.  
A series of transcription factors have been found to collaborate with the core 
factors, constituting an ES cell-specific transcription circuitry. Tcf3, Stat3, Smad1, which 
are components of Wnt, LIF and BMP pathway respectively, are implicated to coregulate 
gene expression with the core factors in ES cells. These factors incorporate external 
signals from the external environment to the transcription circuitry (Chen et al. 2008; 
Cole et al. 2008; Tam et al. 2008). c-Myc, which regulates proliferation and whose 
binding correlates with activation, also colocalizes with the core transcription factors in 
ES cells, suggesting a role in shaping the transcription output (Kim et al. 2008). In 
addition, transcription factors Sall4, Esrrb, Zfx, Tbx3, Rex1 and Klf4 have also been 
connected to the circuitry (Chen et al. 2008; Kim et al. 2008). Such a transcription factor 
network further outreaches to epigenetic regulators, which play special roles in 
maintaining ES cell identity (Orkin and Hochedlinger 2011; Young 2011). 
Epigenetic regulation of embryonic stem cells 
In general, ES cells have “open” chromatin, which is more permissive for 
transcription. It has been observed that heterochromatin is progressively clustered and 
rearranged into foci during differentiation (Wiblin et al. 2005; Meshorer et al. 2006; 
Williams et al. 2006). Chromatin components and chromatin associated proteins, such as 
histones H2B and H3, linker histone H1 and heterochromatin protein HP1, have been 
shown to exchange more vigorously in ES cells than in differentiated cells, suggesting an 
open state for ES cell chromatin (Meshorer et al. 2006). Such a chromatin state, as well 
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as the unique ES cell property, results from the specialized epigenetic regulatory 
mechanisms in ES cells. 
A variety of epigenetic factors, including those mediating histone modifications, 
DNA methylation and chromatin remodeling, have been found to participate in epigenetic 
regulation in ES cells (Jaenisch and Young 2008; Meissner 2010; Orkin and 
Hochedlinger 2011; Young 2011). One of the mechanisms to maintain the ES cell 
property is through the establishment of “bivalent” chromatin structure (Boyer et al. 2005; 
Azuara et al. 2006; Bernstein et al. 2006; Lee et al. 2006). The bivalent structure is 
defined by the coexistence of the repressive mark H3K27me3 and the active mark 
H3K4me3. In ES cells, the bivalent structure covers a large set of differentiation-induced 
genes, whose expression are silenced or “poised” in ES cells. Upon differentiation, the 
bivalency on these loci is resolved and these genes are activated. In ES cells, H3K27me3 
and/or its catalyzing polycomb repressive complex 2 (PRC2) dominates the activating 
mechanisms and keeps the expression of the differentiation-inducing genes poised. 
Although the activity of PRC2 is dispensable for pluripotency maintenance in ES cells, it 
is required for proper differentiation of ES cell (Chamberlain et al. 2008). Consistent with 
that, PRC2 components are crucial for development, as depleting any of them leads to 
early embryonic lethality (Shumacher et al. 1996; O'Carroll et al. 2001; Pasini et al. 
2004).  
In addition to PRC2, other histone modifying enzymes catalyzing repressive 
modifications are also implicated in functioning in ES cell maintenance. polycomb 
repressive complex 1 (PRC1), which catalyzes monoubiquitylation of H2A at lysine 119, 
shares a significant portion of gene targets with PRC2 in ES cells, including the lineage-
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inducing genes (Boyer et al. 2006; Bracken et al. 2006). Setdb1, a histone 
methyltransferase specific for H3K9me3, has been shown to repress genes specific for 
extraembryonic trophoblast lineage in ES cells (Bilodeau et al. 2009; Yuan et al. 2009). 
Furthermore, the trithorax (Trx) complexes, which catalyze H3K4me3, play an important 
role in ES cell differentiation and interact with the core transcription factors (Ang et al. 
2011; Jiang et al. 2011). The Tip40-p300 complex harboring histone acetylation activity 
has been found to be required for ES cell maintenance (Fazzio et al. 2008). Thus, histone 
modifying enzymes carry out diverse functions in regulating ES cell identity. 
In ES cells, DNA methylation pattern shows correlations with histone 
modifications. Promoters with high CpG content, including those of pluripotency genes, 
lack DNA methylation and bear H3K4me3; while promoters with low CpG content, 
including those of lineage specific genes, are hypermethylated and devoid of H3K4me3 
(Mikkelsen et al. 2007; Meissner et al. 2008). Such a pattern indicates that DNA 
methylation likely contribute to the ES cell specific transcription program that controls 
the ES cell state.  Although ES cells deficient in DNA methylation can be derived and 
propagated, these cells cannot differentiate properly (Jackson-Grusby et al. 2001; Jackson 
et al. 2004), suggesting a role of DNA methylation in directing differentiation. 
Chromatin remodeling complexes also play a role in regulating ES cell property. 
An ES-cell specific SWI/SNF family remodeling complex, esBAF, interacts and 
colocalizes with the core transcription factors. The components of esBAF are important 
for ES cell maintenance (Ho and Crabtree 2010). Chd1, a CHD family remodeler, 
localizes onto euchromatin and contributes to transcription activation in ES cells. 
Depletion of Chd1 in ES cells results in preferential differentiation to the neural lineage 
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(Gaspar-Maia et al. 2009). Chd7, another CHD remodeling enzyme, binds to genomic 
loci coregulated by the core transcription factors (Schnetz et al. 2010). All these 
evidences suggest that epigenetic enzymes modulating chromatin play important roles in 
specifying the ES cell state.  
1.4 Generation of induced pluripotent stem (iPS) cells 
Somatic cell reprogramming to pluripotency 
It had been long thought that differentiated somatic cells achieve static cell fates 
by loss of chromosome or permanent gene inactivation during development, before 
somatic cell reprogramming to an embryonic state was achieved. Currently, there are 
three approaches for somatic cell reprogramming: nuclear transfer, cell fusion and 
transcription factor-directed reprogramming (Stadtfeld and Hochedlinger 2010; 
Yamanaka and Blau 2010). In nucleus transfer, the nucleus from a somatic cell is 
transplanted into an enucleated oocyte, and the nucleus reprogramming is initiated by the 
oocyte-derived factors in the cytoplasm. The nuclear transferred oocyte is capable of 
developing into an entire individual, which is a genetically identical clone to the original 
somatic cells (Wilmut et al. 1997; Wakayama et al. 1998). A second approach to 
reprogram somatic cells to pluripotency is fusing somatic cells with pluripotent cells. 
After fusion, the pluripotent cell fate appears to dominate the differentiated one, as the 
nucleus from somatic cells acquires pluripotency in the resulting heterokaryon or hybrid 
cells (Tada et al. 1997; Tada et al. 2001). Recently, a third approach has been established. 
Pluripotency can be induced from somatic cells by ectopic expression of a set of 
transcription factors (Takahashi and Yamanaka 2006). The resultant induced pluripotent 
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stem (iPS) cells are nearly identical to ES cells derived from the ICM of blastocysts 
(Hanna et al. 2010; Stadtfeld and Hochedlinger 2010; Yamanaka and Blau 2010). 
Transcription factor-directed iPS cell generation 
Starting from 24 ES cell-enriched candidate factors, Yamanaka and colleagues 
found that overexpression of Oct4, Sox2, Klf4 and c-Myc is able to convert differentiated 
fibroblasts to an ES cell-like state. The derived iPS cells have ES cell molecular profiles 
and contribute to tissues in developing embryo after injected to blastocysts (Takahashi 
and Yamanaka 2006). Subsequently, iPS cells have been shown to be capable of 
generating chimera and transmitting to germ lines, when core transcription factor, Nanog 
or Oct4, is used as a reporter for pluripotency (Wernig 2004; Maherali et al. 2007b; Okita 
et al. 2007). Later, “all iPS-cell” mice have been generated through tetraploid 
complementation, which is the most stringent test for pluripotency (Boland et al. 2009; 
Kang et al. 2009; Zhao et al. 2009), illustrating that iPS cells derived from transcription 
factor-directed reprogramming bear developmental potential equivalent to ES cells. 
This reprogramming strategy has been successfully applied to a wide range of 
somatic cell types, including terminally differentiated B cells, and across several 
mammalian species, including human (Stadtfeld and Hochedlinger 2010). A range of 
technical approaches have also been developed to introduce the transcription factors, 
including transduction by integrating retrovirus and lentivirus, transduction by non-
integrating adenovirus, plasmid transfection, RNA transfection and protein delivery 
(Stadtfeld and Hochedlinger 2010).  
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Mechanisms of iPS cell generation 
Models for the iPS cell generation process 
Although the derivation of iPS cells is technically well-established, the 
mechanisms underlying the process have just begun to reveal. One of the most puzzling 
issues in iPS cell generation is its low efficiency. The conversion rate from starting cells 
to iPS cells is usually less than 1%, and the reprogramming process takes at least 1 to 2 
weeks. To explain this inefficiency, two models have been raised: the “stochastic” model 
and the “elite” model (Hanna et al. 2009; Yamanaka 2009; Hanna et al. 2010; Stadtfeld 
and Hochedlinger 2010). 
The stochastic model proposes that under the induction of transcription factors all 
somatic cells have equal potential to become iPS cells, and the reprogramming process 
must go through some stochastic events. The strongest evidence for this model comes 
from an elegant study starting with “secondary” lineage purified B cells, which inherently 
harbors inducible reprogramming factors. By monitoring for 18 to 20 weeks, the authors 
showed that nearly all the starting cells are able to generate a population of iPS cells, 
suggesting that nearly all starting cells have the potential to acquire pluripotency (Hanna 
et al. 2009). By mathematical modeling, the author further revealed a sole energy barrier 
during the reprogramming process (Hanna et al. 2009; Hanna et al. 2010). However, 
despite this evidence, a pure stochastic model seems difficult to explain some 
reprogramming observations which could be readily interpreted with the elite model.  
The elite model proposes that certain cells in the reprogramming cell populations 
have advantages for becoming iPS cells. The advantages can be originated from the 
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privileged statuses of some cells among the starting cells. These statuses may include 
differentiation potentials, senescence status and etc. Evidences show that, reprogramming 
starting with hematopoietic stem or progenitor cells has significantly higher efficiency 
than those with fully differentiated hematopoietic cells (Eminli et al. 2009), and senescent 
cells display less reprogramming efficiency cells compared to the proliferative 
counterparts (Utikal et al. 2009). Furthermore, the advantages may also be gained by 
certain cells during the reprogramming process. It has been shown that at the beginning 
of reprogramming some population of cells undergoes rapid changes of morphology and 
proliferation profile, which leads to a high conversion rate to iPS cells compared to the 
overall population (Smith et al. 2010). For these observations, the elite model provides a 
simple and direct explanation. To reconcile all the reprogramming observations, it has 
been suggested that a model with elements from both the stochastic and elite model 
maybe more accurately reflects the iPS cell generation process (Stadtfeld and 
Hochedlinger 2010).  
Generation of iPS cells is a stepwise process 
Generation of iPS cell has been portrayed as a stepwise process with multiple 
“roadblocks”, and somatic cells driven by the transcription factors must conquer these 
roadblocks to achieve pluripotency. It has been thought that, along the reprogramming 
process, fewer and fewer cells manage to pass each roadblock, which leads to the 
inefficiency of the final yield of iPS cells (Stadtfeld and Hochedlinger 2010; Plath and 
Lowry 2011). Induction of proliferation, upregulation of epithelial genes and 
downregulation of some somatic cell gene are among the early events occurring during 
reprogramming. By time-lapse imaging, cells that successfully become iPS cells were 
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traced back to a population of cells that acquire a high proliferation rate and a compact 
size within the first day in the reprogramming process (Smith et al. 2010). Epithelial 
genes, which is expressed in ES cells but silenced in fibroblasts, have been shown to be 
activated early in reprogramming, which leads to a radical change in adhesion property 
and morphology of the reprogramming cells (Li et al. 2010; Samavarchi-Tehrani et al. 
2010). By cell sorting, downregulation of fibroblasts surface marker Thy1 has also been 
shown to occur in the early stage of reprogramming (Stadtfeld et al. 2008). Cells that pass 
all these early roadblocks gradually acquire pluripotency, sequentially activating ES cell 
markers alkaline phosphatase, SSEA-1, Nanog and endogenous Oct4 (Brambrink et al. 
2008; Stadtfeld et al. 2008). Once the transcription circuitry for pluripotency is 
established, the exogenous transcription factors become dispensable. Further “maturation” 
steps are probably needed for the nascent iPS cells to reactive inactivated X chromosome 
(Stadtfeld et al. 2008), erase the epigenetic memory of somatic cells completely (Polo et 
al. 2010) and fine-tune the pluripotent circuitry (Samavarchi-Tehrani et al. 2010).   
Roles of the introduced transcription factors 
Revealing the roles of the introduced transcription factors in iPS cell generation is 
essential for illuminating the reprogramming mechanisms. By genome wide localization 
studies, it has been found that the introduced factors bind to targets similar to those in ES 
cells (Sridharan et al. 2009a). Oct4 and Sox2, members of the core transcription triad in 
ES cells, bind to ES-cell enriched gene in reprogramming, and Klf4 collaborate with 
them by co-occupying half of their targets (Jiang et al. 2008; Kim et al. 2008; Sridharan 
et al. 2009a). Collaboration of these three factors is thought to be crucial for establishing 
the pluripotency network. Furthermore, Klf4 individually can activate some of the 
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epithelial genes, whose activation occurs early in reprogramming, suggesting a 
specialized role of in acquiring the epithelial property (Li et al. 2010).  
Unlike Oct4, Sox2 and Klf4, c-Myc appears to play a different role in 
reprogramming. It binds to a distinct set of targets that function in cell proliferation, 
metabolism and biosynthetic pathway and functions early in reprogramming (Mikkelsen 
et al. 2008; Sridharan et al. 2009a). Furthermore, although it greatly enhances iPS cell 
generation, c-Myc is dispensable for iPS cell derivation (Nakagawa et al. 2008; Wernig et 
al. 2008). c-Myc has been shown to promotes transcription elongation (Rahl et al. 2010) 
and facilitate the establishment of active chromatin environment (Knoepfler 2008). 
Therefore, it is likely that c-Myc generally contributes to gene activation, which is 
directed by other introduced reprogramming factors.  
Additional factors that affect iPS cell generation 
Currently, a variety of additional factors, including transcription factors, 
chromatin modulators, miRNAs, growth factors and chemical compounds have been 
found to affect the reprogramming process (Feng et al. 2009; Stadtfeld and Hochedlinger 
2010). Understanding how these factors contribute to reprogramming helps uncover the 
mechanisms of iPS cell generation.  
Nanog, despite its essential role in maintaining pluripotency in ES cell, was not 
among the factors originally identified by Yamanaka and colleague (Takahashi and 
Yamanaka 2006). However, later, it has been found that, although Nanog is not required 
for the initiation of reprogramming, it facilitates the transitions from intermediate cells to 
iPS cells and enhances reprogramming efficiency (Hanna et al. 2009; Silva et al. 2009). 
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In addition, Nanog has been identified in the cocktail of transcription factors inducing 
human iPS cells, together with Oct4, Sox2 and Lin28 (Yu et al. 2007), again suggesting 
an important role of Nanog in establishing pluripotency in iPS cell.  
Modulations of cell proliferation status have also been found to affect 
reprogramming. Depletion of p53-p21 pathway and suppression of Ink4a/Arf accelerate 
the reprogramming kinetics and enhance reprogramming efficiency (Banito et al. 2009; 
Hanna et al. 2009; Hong et al. 2009; Kawamura et al. 2009; Li et al. 2009; Utikal et al. 
2009). Enhanced proliferation has been suggested to facilitate epigenetic changes 
presumably by efficient resetting the chromatin states in S phase (Hanna et al. 2009; 
Plath and Lowry 2011).   
Given that acquiring epithelial properties and eliminating mesenchymal ones are 
among the steps in reprogramming from fibroblasts to iPS cells, factors promoting 
mesenchymal-epithelial transition (MET) and/or inhibiting epithelial-mesenchymal 
transition (EMT) are capable of facilitating reprogramming. These factors include 
agonists of BMP pathways, inhibitors of Tgf-β pathway and miRNA clusters miR-200s 
(Ichida et al. 2009; Maherali and Hochedlinger 2009; Li et al. 2010; Samavarchi-Tehrani 
et al. 2010).  
Factors that target chromatin have been also shown to play a role in iPS cell 
generation. Components of the BAF chromatin remodeling complex are capable of 
enhancing reprogramming efficiency (Singhal et al. 2010). Chemicals that inhibit DNA 
methylation, histone deacetylation or histone H3 K9 methylation are also capable of 
promoting iPS cell generation (Huangfu et al. 2008a; Mikkelsen et al. 2008; Shi et al. 
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2008a). Interestingly, all these epigenetic modulators leads to a permissive chromatin, 
suggesting that counteracting the suppressive chromatin state in somatic cell may be a 
crucial step for reprogramming.  
To summarize, various additional factors acts on the reprogramming process from 
different aspects. Identifying novel factors that contribute to iPS cell generation is one of 
the strategies to understand the mechanisms of reprogramming.   
1.5 Introduction to the research within the dissertation 
Generation of iPS cells attracts huge attention for its tremendous clinical 
potentials in regenerative medicine; however, the low efficiency and the insufficient 
mechanistic knowledge of the reprogramming process cast uncertainty on the future 
application of iPS cells. To improve the iPS cell derivation process and advance our 
understanding of reprogramming mechanisms, I aimed to identify epigenetic modulators 
that facilitate iPS cell generation, based on the premise that all cell fate transitions, 
including reprogramming to iPS cells, are fundamentally epigenetic processes.  
I first focus on the chemical epigenetic modulators and found that butyrate, a 
histone deacetylase inhibitor, promotes iPS cell generation, Butyrate not only increases 
iPS cell number and changes the reprogramming dynamics, but also reduces the 
frequency of partially reprogramming cells. The facilitation by butyrate occurs early in 
reprogramming and depends on the presence of c-Myc. Genome-wide expression study 
reveal the upregulation of ES cell enriched genes in the presence of butyrate. This 
research strengthens the viewpoint that reversing the repressive chromatin structure is 
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crucial for reprogramming to iPS cells. This part of my research will be presented in 
Chapter Two.  
Next I probed for the potential effect of ES cell-enriched epigenetic factors, which 
potentially help establish the ES cell state, and found that Kdm2b, a histone demethylase 
specific for H3K36me2, is capable of enhancing iPS cell generation. Details studies 
reveal that, the Kdm2b-directed enhancement is independent of its role in promoting cell 
proliferation or suppressing senescence, but relies on its effect on activating early 
epithelial transcription program. Microarray and gene ontology analysis indicates that 
there likely exists a switch from an epithelial transcription program to a pluripotent 
program during iPS cell generation. For that, I propose a transcription cascade model for 
iPS cell generation and address the role of Kdm2b using this model. This part of my 
research will be elaborated in Chapter Three. 
Overall, research in this dissertation not only shows that manipulation of 
epigenetic statuses is a way to improving iPS cell generation, but also shed light on the 
reprogramming mechanisms by highlighting the importance of epigenetic modifications.  
  
                                                                                                                            
 
 
CHAPTER 2  BUTYRATE PROMOTES INDUCED PLURIPOTENT STEM 
CELL GENERATION
*
 
2.1 Introduction 
Reprogramming from somatic cells to induced pluripotent stem (iPS) cells can be 
achieved by retroviral expression of transcription factors Oct4, Sox2, Klf4 and c-Myc 
(Takahashi and Yamanaka 2006; Maherali et al. 2007a; Okita et al. 2007; Wernig et al. 
2007). However, the slow reprogramming process and low reprogramming efficiency 
impede detailed mechanistic studies and potential applications of this technology. One 
solution to overcome these problems is to identify small molecules that can enhance the 
reprogramming efficiency. Indeed, recent studies have demonstrated that several 
chemicals with the capacity to modulate epigenetic enzymes exhibit positive effects on 
iPS cell generation. For example, valporic acid (VPA), a histone deacetylase inhibitor, 
has been shown to improve both the kinetics and efficiency of mouse and human iPS cell 
generation (Huangfu et al. 2008a; Huangfu et al. 2008b). In addition, BIX-01294, an 
inhibitor for the histone methyltransferase G9a, and RG108, a DNA methyltransferase 
(DNMT) inhibitor, have been reported to enhance the efficiency of iPS cell generation 
(Shi et al. 2008a; Shi et al. 2008b). Furthermore, another DNMT inhibitor, 5-aza-cytidine, 
has been shown to facilitate the conversion of partially reprogrammed cells to fully 
reprogrammed iPS cells (Mikkelsen et al. 2007).  
                                                 
*
 Adapted from Liang G, Taranova O, Xia K, Zhang Y. 2010. J Biol Chem 285: 25516-
25521.  
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Recently, butyrate, a naturally occurring short-chain fatty acid and histone 
deacetylase inhibitor, has been shown to support self-renewal of both human and mouse 
embryonic stem (ES) cells in a range of relatively low concentrations (Ware et al. 2009). 
However, butyrate has also been reported to induce differentiation when applied at higher 
concentrations (Newmark et al. 1994). Therefore, whether butyrate has an effect on iPS 
cell generation is an intriguing question. In this report, we sought to examine the effect of 
butyrate on iPS cell generation. We found that butyrate facilitates iPS cell generation in 
the range of 0.5 to 1 mM. This effect appears to be mediated through one of the 
reprogramming factors c-Myc. In addition, butyrate is able to increase the percentage of 
fully reprogrammed iPS cells by reducing partially and/or unsuccessfully reprogrammed 
cells. Genome-wide gene expression analysis indicates that butyrate can specifically 
increase the expression of some ES cell-enriched genes in fibroblasts in the presence of 
exogeneous c-Myc. Thus our studies uncover another chemical capable of facilitating iPS 
cell generation, contributing to the iPS cell tool box. 
2.2 Results 
Butyrate promotes iPS cell generation  
A recent study indicated that butyrate, a small fatty acid, supports self-renewal in 
mouse and human embryonic stem cells (Ware et al. 2009). To determine whether 
butyrate has an effect in iPS cell generation, we transduced 1×10
5
 MEFs derived from 
hemizygote Sox2-GFP mice with retroviruses expressing Oct4, Sox2, Klf4 and c-Myc in 
the presence of varying concentrations of butyrate. The effect of butyrate on 
reprogramming was monitored for a period of 12 days after infection. In the presence of 
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butyrate, GFP+ colonies with ES cell-like morphology were observed at day 6 post-
infection (Figure 2-1A). At day 8, we observed a dose-dependent enhancement of 
reprogramming efficiency when butyrate was used at concentrations between 0.25−1 mM. 
A maximum of 7-fold increase was observed when butyrate was applied at 1 mM 
concentration. However, at higher concentrations (1.5 and 2 mM), butyrate becomes cell 
toxic and no GFP positive colonies were observed (Figure 2-1B). On day 12, treatment of 
butyrate at 0.5 and 1 mM still showed an approximate 2-fold increase in the number of 
GFP positive colonies (Figure 2-1B, right panel, green bars). The effect of butyrate on 
promoting the generation of GFP positive iPS colonies is comparable to that of VPA 
(Figure 2-1B).  
In addition to counting the GFP positive iPS cell colony numbers, we also 
counted the total and the alkaline phosphatase (AP) positive colony numbers on day 12. 
Interestingly, at lower concentrations of butyrate (0.25−1 mM), both the AP+ and total 
colony numbers show a concentration-dependent reduction (Figure 2-1B, right panel), 
although more GFP+ colonies were observed. This leads to exceptionally high 
GFP+/AP+ and GFP+/total colony ratios under butyrate treatment, which is distinct from 
the effect of VPA (Figure 2-1B, right panel). For example, in the absence of butyrate, 
only 20% of the total colonies are GFP+ and 63% are AP+; at the concentration of 0.5 
mM, 66% are GFP+ and 83% are AP+; at the concentration of 1 mM, these ratios are 
further increased to 92% and 96% respectively (Figure 2-1B, right panel and Figure 2-
1C). Since Sox2-GFP is a more stringent pluripotency marker than AP, the reduction of 
GFP− colonies in total population and AP+ population suggests that butyrate is capable 
of suppressing the formation of transformed cells or partially reprogrammed cells that 
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were not destined to the pluripotent cell fate. This observation is consistent with the well-
characterized effect of butyrate on limiting the cell growth of cancerous cells (Bolden et 
al. 2006). 
Butyrate accelerates iPS cell generation and its effect is c-Myc dependent  
To further characterize the effect of butyrate on iPS cell generation, we monitored 
the effect of butyrate (1 mM) on the kinetics of reprogramming by introducing the four 
transcription factors (4F; Oct4, Sox2, Klf4 and c-Myc) and 3 factors (3F; Oct4, Sox2 and 
Klf4). In the case of 4F reprogramming, butyrate accelerated formation of GFP+ colonies 
by 2-3 days until post-infection day 16 when the effect of butyrate on the GFP+ colony 
number becomes unnoticeable (Figure 2-2A). However, when the reprogramming was 
performed using three factors, butyrate appears to have a negative effect on 
reprogramming efficiency (Figure 2-2A). This suggests that the enhancement effect of 
butyrate on reprogramming is dependent on exogeneous c-Myc under our experimental 
condition. We also monitored the number of AP+ colony and total colony at post-
infection day 12. In both 4F and 3F reprogramming, butyrate strongly reduces the total 
colony number and GFP− colony number (Figure 2-2B), indicating that butyrate is 
capable of limiting the formation of partially reprogrammed cells or transformed cells 
regardless of whether three factors or four factors were used for reprogramming. In 
addition, we also tested the potential effect of butyrate on reprogramming by 
withdrawing other factors from the 4F combination; however, we did not observe any 
positive effect of butyrate on reprogramming under these conditions (data not shown). 
                                                                                                                            
26 
 
Sox2-GFP positive colonies are pluripotent  
Next we set out to characterize the GFP+ colonies generated in the presence of 
butyrate. To this end, individual GFP+ colonies were picked-up and propagated in 
standard ES cell culture medium in the absence of butyrate. All of the GFP+ colonies 
derived in the presence of butyrate exhibit ES-like morphology (Figure 2-3A) and high 
alkaline phosphatase activity (Figure 2-3B). We randomly picked three colonies for 
further characterization. RT-PCR analysis demonstrated that all three lines expressed 
endogenous stem cell factors Oct4, Sox2, Nanog, as well as other pluripotency-related 
genes, such as  Fbxl15 and Utf1 (Figure 2-3C). When these iPS cells were injected into 
immunodeficient mice, all lines were able to form complex-structured teratoma 
containing tissues of the three germ layers (Figure 2-3D). Collectively, these results 
suggest that Sox2-GFP+ cells generated in the presence of butyrate are pluripotent. 
Butyrate facilitates iPS cell generation in an early time window  
To shed light on the role of butyrate in promoting iPS cell generation, we sought 
to determine the time window during which butyrate exerts its effect. First, butyrate was 
applied to the culture media immediately after infection and was withdrawn from the 
media at different time points during the 12-day reprogramming process (Figure 2-4A, 
left panel). Successfully reprogrammed GFP+ colonies were counted at day 12 and the 
effect of butyrate on reprogramming was determined by comparison to GFP+ colony 
numbers in the absence of butyrate. Results shown in Figure 2-4A (right panel) 
demonstrate that the exposure to butyrate for only 2−4 days following transduction has a 
similar effect as that of continued exposure during the reprogramming process. Next, we 
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determined whether the 2−4 days of butyrate treatment needed to be performed at a 
particular time point during the reprogramming process. To this end, butyrate was added 
to the culture media at different time points during the reprogramming process (Figure 2-
4B, left panel) and the effect of butyrate on reprogramming was determined in a similar 
way as that described above. Interestingly, we found that exposure to butyrate for 2 days 
after transduction has the maximum positive effect on the efficiency of reprogramming. 
Based on the above experiments, we conclude that butyrate exhibits the maximum effect 
on iPS cell generation at the initial 2−4 days of reprogramming, suggesting that butyrate 
functions early during the reprogramming process. Our finding that butyrate exerts its 
effect in a c-Myc-dependent manner (Figure 2-2) and that this occurs early during the 
reprogramming process is consistent with previous studies demonstrating that c-Myc 
mainly contributes to reprogramming at an early stage (Sridharan et al. 2009b).  
Butyrate up-regulates a set of ES cell-enriched genes in c-Myc-mediated 
reprogramming  
To gain insight into the molecular mechanism of butyrate enhanced 
reprogramming, we carried out gene expression studies using cDNA microarrays with the 
following four samples: i) 4F transduction, ii) 4F transduction with butyrate treatment 
(4F+B), iii) 3F transduction, and iv) 3F transduction with butyrate treatment (3F+B). 
Because the effective time window for butyrate is 2-4 days after infection, and since we 
are mainly interested in a primary effect, we treated the transduced MEFs with butyrate 
for a period of 48 hrs prior to harvesting RNA. We first focused on the genes whose 
expression is at least 8-fold higher in ES cells than in MEFs (Mikkelsen et al. 2007). We 
plotted the expression level of these ES cell-enriched genes in 4F (Figure 2-5A, red dots) 
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and 3F (blue dots) transduced MEFs at day 4 on a scatter chart, in which x and y axis 
respectively represent the expression level in the absence or presence of butyrate (Figure 
2-5A). Linear regression of the scatter plot show that the slope of the 4F regression line 
(1.3137) is significantly higher than that of the 3F regression line (1.0918), indicating that 
the expression of these stem cell enriched genes as a whole is increased by butyrate 
treatment in a c-Myc-dependent manner (Figure 2-5A). Similarly, we have also analyzed 
the expression of MEF-enriched genes in response to butyrate treatment in 
reprogramming. However, a significant down-regulation of these genes due to the 
treatment of butyrate was not noticed, regardless of whether 4F or 3F were used in 
reprogramming (data not shown). 
Further analysis of the microarray data indicate that a total of 337 probes were at 
least 2-fold up-regulated by the treatment of butyrate in the 4F reprogramming, while 
only 182 probes were up-regulated at least 2-fold in 3F reprogramming (Figure 2-5B). 
Interestingly, 199 out of the 337 probes up-regulated in the 4F reprogramming appear to 
be c-Myc-dependent as butyrate treatment failed to significantly up-regulate them in the 
3F reprogramming. Among the 199 probes, 21 probes correspond to 19 known ES cell-
enriched genes (Table S2-1). RT-qPCR analysis of randomly selected genes out of the 19 
ES cell-enriched genes confirmed that their expression is significantly up-regulated by 
the treatment of butyrate in the 4F reprogramming, but not in the 3F reprogramming 
(Figure 2-5C). The selected genes, Bex1, Mreg and Krt12 are most up-regulated by 
butyrate at the concentration of 1 mM (Figure S2-1), which is consistent with the 
observed maximum effect of butyrate on iPS cell generation at this concentration. How 
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up-regulation of these genes contributes to the iPS cell generation process remains to be 
determined.  
2.3 Discussion 
In this study, we demonstrate that butyrate, a small fatty acid and histone 
deacetylase inhibitor, promotes mouse iPS cell generation by Oct4, Sox2, Klf4 and c-
Myc. Under the optimal concentration (0.5−1 mM), butyrate can enhance the generation 
of Sox2-GFP positive iPS cells by 7-fold when the four factors were used in 
reprogramming (Figure 2-1B). Butyrate facilitates iPS cell generation mainly by shifting 
the kinetic of 4F reprogramming 2-3 days forward (Figure 2-2A). A recent study 
indicated that ES cell self-renewal is facilitated by the presence of butyrate at a lower 
concentration (around 0.2 mM) (Ware et al. 2009). Given that butyrate can relax the 
chromatin structure by functioning as a histone deacetylase inhibitor, a higher (0.5-1 mM) 
optimal concentration in 4F reprogramming might indicate that establishment of 
pluripotency may need more accessible chromatin structure compared with that required 
for maintenance of ES cell status. Although butyrate is widely used as a differentiation 
reagent when applied at a higher concentration (≥ 1 mM) (Newmark et al. 1994), we did 
not notice differentiation of the fully reprogrammed Sox2-GFP+ colonies during the time 
of butyrate treatment. Neither do we observe any negative effect of butyrate on the 
quality of iPS cells derived in the presence of butyrate. The apparent conflicting roles that 
butyrate displays in differentiation and iPS cell generation suggest that this epigenetic 
modulator may generally facilitate cell fate changes by increasing the flexibility of 
chromatin. In this regard, it will be interesting to test whether butyrate can facilitate 
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transdifferentiation between different cell types, for example from fibroblasts to muscle 
cells (Davis et al. 1987) and from B cells to macrophage (Xie et al. 2004).  
In addition to facilitating iPS cell generation, we also noticed that butyrate can 
reduce the GFP negative colony numbers, regardless of their AP activity status. This 
effect results in a significant increase in the ratio of GFP+ colonies, representing 
authentically reprogrammed iPS cells (Fig 1B and C). The AP− GFP− colonies are 
probably cells that failed to express all four reprogramming factors. These cells usually 
exhibit properties of transformed cells, such as granulated or cobblestone morphology 
with fast cell growth (Takahashi and Yamanaka 2006). Elimination of these AP− GFP− 
colonies can be attributed to the well-characterized anti-cancer effect of butyrate (Bolden 
et al. 2006), including induction of p21/Cdkn1a and p19/Arf (Figure S2-1). On the other 
hand, AP+ GFP− colonies most likely represent partially reprogrammed cells that 
somehow have not achieved the pluripotent cell fate (Mikkelsen et al. 2007; Sridharan et 
al. 2009b). With the assistance of butyrate, these partially reprogrammed cells may gain 
full pluripotency and express Sox2-GFP contributing to the observed higher 
reprogramming efficiency. We note that although VPA, another histone deacetylase 
inhibitor, can also increase the GFP+ colony number, it does not seem to have the same 
capacity to suppress the total colony numbers (Figure 2-1B). Another epigenetic 
modulator, 5-aza-cytidine, has been shown capable of facilitating conversion of partially 
reprogrammed cells to fully reprogrammed cells (Mikkelsen et al. 2007). It will be 
interesting to test whether butyrate has a similar property. Given that butyrate functions at 
an early stage of reprogramming, while 5-aza-cytidine facilitates conversion of partially 
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reprogrammed cells to fully reprogrammed cells, it will be interesting to test whether they 
can function synergistically to facilitate the reprogramming process.  
Since reprogramming is a process with multiple steps (Brambrink et al. 2008; 
Stadtfeld et al. 2008), we determined the functioning time window of butyrate to be at an 
early stage of the reprogramming process (Figure 2-4). This is consistent with our finding 
that butyrate facilitates reprogramming only in the presence of exogeneous c-Myc 
(Figure 2-2) as c-Myc has been suggested to contribute to the early events of 
reprogramming (Sridharan et al. 2009b). To explore the effect of butyrate in the early 
reprogramming process at the molecular level, we analyzed the genome-wide expression 
profiles of cells undergoing reprogramming in this time window. We observed a trend of 
up-regulation for ES cell-enriched genes in response to butyrate (Figure 2-5A), but did 
not detect genome-wide down-regulation of MEF-enriched genes (data not shown). This 
observation is consistent with the role of butyrate in gene activation as a histone 
deacetylase inhibitor. Furthermore, we identified 19 ES-enriched genes that are 
specifically up-regulated by butyrate only when c-Myc is included as a reprogramming 
factor (Table S2-1). It remains to be determined whether up-regulation of these genes 
mediates the effect of butyrate. Given that reprogramming efficiency can be increased by 
suppression of the p53-p21 pathway (Hanna et al. 2009; Hong et al. 2009; Kawamura et 
al. 2009; Marion et al. 2009) as well as elimination of the senescence barrier imposed by 
Ink4a and/or Arf (Li et al. 2009; Utikal et al. 2009), we also analyzed whether butyrate 
can suppress the expression of p53, p21, Ink4a and Arf. Instead of down regulation, we 
indeed observed a slight up-regulation of some of these genes (p21 and Arf) by the 
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butyrate treatment (Figure S2-2), largely excluding the involvement of p53-p21 pathway 
in mediating the butyrate effects.  
During the preparation of this manuscript, Mali et al. reported that butyrate 
greatly facilitates human iPS cell generation (Mali et al. 2010). In their report, 
reprogramming efficiency is increased remarkably by butyrate even in the absence of c-
Myc and Klf4. Another difference between these two studies is the timing at which 
butyrate exhibits its effect. While it exerts an effect at an early stage during 
reprogramming in mouse cell reprogramming, Mali et al reported a later effect in human 
cells (Mali et al. 2010). Furthermore, while we noticed an inhibitory effect for 
transformed cells and partially reprogrammed cells, it is not clear whether a similar effect 
is seen in human cells. Whether these differences are due to the endogenous c-Myc levels, 
the different times required to achieve reprogramming for human and mouse MEFs, or 
other technical aspects remains to be determined. Nonetheless, the demonstration that 
butyrate, an HDAC inhibitor, is capable of facilitating iPS cell generation suggests that 
alteration of epigenetic status is an important step for the establishment of pluripotency. 
2.4 Materials and methods 
MEF derivation and iPS cell culture 
Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos of Sox2-
GFP/Rosa26-M2rtTA double knock-in mice. MEFs were cultured in rich fibroblast 
growth medium (Dulbecco’s modified Eagle’s medium [DMEM] supplemented with 15% 
fetal bovine serum [FBS], non-essential amino acid [NEAA], GlutaMax, and 
penicillin/streptomycin) for no more than 2 passages before retroviral transduction. iPS 
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cells were cultured in mouse ES cell medium (DMEM with 15% FBS, NEAA, GlutaMax, 
sodium pyruvate, β-mercaptoethanol, penicillin/streptomycin and 1,000 U/ml leukemia 
inhibitory factors) with mytomycin C-treated STO cells as feeder cells or on 0.1% 
gelatin-coated plates.  
Retrovirus preparation and infection 
Retroviral plasmids pMXs expressing murine Oct4, Sox2, Klf4 and c-Myc 
(Takahashi and Yamanaka 2006) were transfected respectively into 293T cells with 
packaging plasmids pGag-pol and pVSVG. Virus-containing supernatants were harvested 
at 48 h and 72 h after transfection and were filtered through 0.45-µm filter membrane and 
concentrated by spin column, before being used in MEF transduction in the presence of 
polybrene (5 µg/ml). 
Generation of iPS cells and calculation of reprogramming efficiency 
MEFs were seeded in 6-well plates with 1×10
5
 cells per well, 16 h before the first 
infection. Concentrated viruses were applied to MEFs twice within 48 h. The day when 
viral supernatant was removed was defined as day 0 post-infection. Transduced 
fibroblasts were then cultured in mouse ES cell medium in the presence or absence of 
butyrate in 12-16 days period. The concentration of butyrate used is 1 mM, except stated 
otherwise. In most cases, reprogramming efficiency is represented by the Sox2-GFP+ 
colony number derived from 1×10
5 
MEFs; in some case, relative reprogramming 
efficiency is also used, which is the fold change of Sox2-GFP+ colony number with 
butyrate treatment compared to that without treatment. Alkaline phosphatase (AP) 
staining was performed with alkaline phosphatase detection kit (Millipore). 
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Teratoma formation and analysis 
Teratomas were induced by subcutaneously injecting 1×10
6  
iPS cells into Rag2-/-
::γC-/- immunodeficient mice. Xenografted tumor samples were isolated from mice in 
four to six weeks, fixed by 4% paraformaldehyde, embedded in paraffin and processed 
for hematoxyin and eosin staining, using standard protocols.  
Quantitative and semi-quantitative RT-PCR 
Total RNAs were harvested using RNeasy kit (Qiagen). Primers for quantitative 
and semi-quantitative RT-PCR are listed in Table S2-2. Quantitative PCR reactions were 
performed with SYBR GreenER mix (Invitrogen). Relative gene expression levels were 
normalized to Gapdh mRNA. 
Genome-wide expression analysis 
2 µg of total RNA were reverse-transcribed into cDNA with a T7-(dT)24 primer 
from a custom kit (Life Technologies). Biotinylated cRNA was then generated from the 
cDNA reaction using the BioArray High Yield RNA Transcript Kit. The cRNA was then 
fragmented in fragmentation buffer (40 mM Tris-acetate, pH8.1, 100 mM KOAc and 150 
mM MgOAc) at 94°C for 35 minutes before microarray hybridization. 15 µg of 
fragmented cRNA was then added to a hybridization cocktail (0.05 µg/µl fragmented 
cRNA, 50 pM control oligonucleotide B2, BioB, BioC, BioD, and cre hybridization 
controls, 0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated BSA, 100 mM MES, 1 M 
[Na+], 20 mM EDTA, 0.01% Tween 20). 10 µg of cRNA were used for hybridization to 
Affymetrix GeneChip Mouse Genome 430A 2.0 Array. Hybridization was carried out at 
45°C for 16 hours. The array was then washed and stained with R-phycoerythrin 
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streptavidin, before scanning. Washing, scanning and basic analysis was carried out using 
Affymetrix GeneChip Microarray Suite 5.0 software. 
Western blotting 
Cell populations were collected at day 2 post-infection and lysed with RIPA 
buffer (150 mM NaCl, 50 mM Tris, pH7.5, 1% NP40, 0.05% Na-deoxycholate, 1 mM 
Na3VO4 and 1 mM NaF) for 1 h at 4°C. Soluble faction, as total protein extract, was 
isolated by centrifugation and then subjected to electrophoresis. Western blotting was 
performed with antibodies against p53 (Santa Cruz, sc6243), p21 (Santa Cruz, sc52870), 
Ink4a (Santa Cruz, sc1207), Arf (Santa Cruz, sc32748) and α-tubulin (Sigma, T6199). 
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Figure 2-1 Butyrate promotes iPS cells generation.  
(A) A representative Sox2-GFP positive iPS cell colony generated in the presence of 
butyrate at post-infection day 6. Scale bar, 100 µm. Mouse embryonic fibroblasts (MEFs) 
from hemizygote Sox2-GFP mouse were transduced with Oct4, Sox2, Klf4 and c-Myc 
(4F), and treated with butyrate. (B) GFP+ colony numbers counted at day 8 (left panel) 
post transduction of 1x10
5
 MEFs with the four reprogramming factors in the absence or 
the presence of various concentration (0.25, 0.5, 1, 1.5 and 2 mM) of butyrate or VPA (1 
mM). Presented in the right panel are the numbers of GFP-positive and total colony 
counted at day 12 post transduction. Subsequently, cells were stained for alkaline 
phosphatase (AP). The number of GFP-positive colonies (green), AP-positive GFP-
negative colonies (purple), and AP-negative GFP-negative colonies (grey) are shown in 
the chart. (C) Representative fluorescent microscopic pictures taken at day 12 post 
transduction by 4F and 4F in the presence of 0.5 mM butyrate (4F+B). Arrows indicate 
Sox2-GFP positive colonies. Scale bar, 1 mm.  
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Figure 2-2 Butyrate improves the reprogramming kinetics in a c-Myc-dependent 
manner.  
(A) Kinetics of reprogramming in the presence of butyrate. Sox2-GFP MEFs transduced 
with 4F and 3F were treated with butyrate (1 mM). The number of GFP-positive colonies 
for each treatment was counted at different days until day 16 post-transduction. (B) GFP-
positive colonies and total colonies were counted at day 12. AP-positive colonies were 
also counted, after cells were stained for AP. 
 
 
  
                                                                                                                            
39 
 
Figure 2-3 iPS cells generated in the presence of butyrate are pluripotent. 
(A) Representative pictures of an iPS cell line derived in the presence of butyrate. iPS 
cell lines derived from 4F reprogramming in the presence of butyrate were cultured in ES 
cell medium on gelatin-coated plates without feeder cells. Scale bar, 100 µm.  (B) iPS 
cells derived in the presence of butyrate is AP positive. Scale bar, 100 µm. (C) RT-PCR 
demonstrate that three randomly picked iPS cell lines derived in the presence of butyrate 
express pluripotent marker genes. (D) Representative pictures of teratoma derived from 
butyrate-assisted iPS cell lines comprise of cell types from all three germ layers 
(endoderm, mesoderm and ectoderm). Scale bar, 100 µm. All three randomly picked iPS 
cell lines showed a similar capacity in generating teratomas harboring cells belonging to 
the three germ layers. 
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Figure 2-4 Butyrate facilitates iPS cell generation at an early time window during 
reprogramming.  
(A) Sox2-GFP MEFs transduced with 4F were treated with butyrate immediately after 
transduction with 4F and butyrate was removed from the culture media at different time 
points and the GFP+ colonies are counted at day 12. The reprogramming efficiencies of 
various treatments were compared to that without the butyrate treatment and presented on 
the right panel. (B) Sox2-GFP MEFs transduced with 4F were treated with butyrate at 
different time after transduction with 4F and butyrate was maintained in the culture 
media till day 12 when the GFP+ colonies are counted. The reprogramming efficiencies 
of various treatments were compared to that without the butyrate treatment and presented 
on the right panel. 
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Figure 2-5 Butyrate enhances the expression of a set of ES cell-enriched genes in 
a c-Myc-dependent manner.  
(A) Global gene expression was analyzed by microarray (Affymetrix) using total RNA 
samples harvested 2 days after mock or butyrate treatment. The expression levels of ES 
cell-enriched genes from samples with butyrate treatment (y-axis) are plotted against 
those without butyrate treatment (x-axis). The expression from cells transduced with 4F 
and 3F are respectively shown in red square and blue diamond. The linear regression line 
for 4F (red, y = 1.3137x – 10.675, R2 = 0.8705) is significantly different (p < 0.05) from 
that of 3F (blue, y = 1.0918x + 2.5027, R
2
 = 0.9653). (B) Venn diagram depicting probes 
of genes that have 2-fold up-regulation in response to butyrate treatment in 4F (B-up’ed, 
4F) or 3F (B-up’ed, 3F) reprogramming. A total of 199 probes that are up-regulated by 
butyrate in 4F, but not 3F, reprogramming were analyzed further. (C)  RT-qPCR 
verification of 3 randomly picked ES cell-enriched genes listed in Table S2-1, Mreg, 
Krt12 and Bex1. Data presented is normalized to Gapdh. 
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Figure S2-1 Expression of butyrate up-regulated genes in response to different 
concentration of butyrate.  
Total RNA samples harvested 2 days after mock or butyrate treatment (0.25 mM, 0.5 mM 
and 1 mM) were subjected to RT-qPCR using primers specific for Bex1, Mreg and Krt12. 
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Figure S2-2 Butyrate treatment does not significantly suppress the p53-p21 
pathway or Ink4a/Arf level.  
(A) RT-qPCR analysis of the various samples with or without the treatment of butyrate 
indicates that butyrate treatment does not significantly suppress the p53-p21 pathway or 
Ink4a/Arf level in promoting the reprogramming. (B)  Western blot analysis confirmed 
the RT-qPCR analysis presented in panel A, supporting the conclusion that butyrate 
treatment does not significantly suppress the p53-p21 pathway or Ink4a/Arf, excluding its 
involvement in mediating the butyrate effect. 
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Table S2-1 Probes of ES cell-enriched genes that are 2-fold up-regulated by 
butyrate in 4F reprogramming, 3F reprogramming and both. 
Probe ID Symbol Name 
Up-regulated only in 4F reprogramming 
1432466_a_at Apoe apolipoprotein E 
1418687_at Arc activity regulated cytoskeletal-associated protein 
1448595_a_at Bex1 brain expressed gene 1 
1449887_at Chmp4c chromatin modifying protein 4C 
1418709_at Cox7a1 cytochrome c oxidase, subunit VIIa 1 
1434170_at Dcaf12l1 DDB1 and CUL4 associated factor 12-like 1 
1416579_a_at Epcam epithelial cell adhesion molecule 
1417883_at Gstt2 glutathione S-transferase, theta 2 
1449074_at Kcnk4 potassium channel, subfamily K, member 4 
1419230_at Krt12 keratin 12 
1457314_at L1td1 LINE-1 type transposase domain containing 1 
1416236_a_at Mpzl2 myelin protein zero-like 2 
1448265_x_at Mpzl2 myelin protein zero-like 2 
1437250_at Mreg melanoregulin 
1429013_at Mtap7d2 MAP7 domain containing 2 
1438820_at Rnf17 ring finger protein 17 
1416627_at Spint1 serine protease inhibitor, Kunitz type 1 
1448562_at Upp1 uridine phosphorylase 1 
1431786_s_at 1190003J15Rik RIKEN cDNA 1190003J15 gene 
1417797_a_at 1810019J16Rik RIKEN cDNA 1810019J16 gene 
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1455918_at   
Up-regulated only  in 3F reprogramming 
1434073_at Gprasp2 
G protein-coupled receptor associated sorting 
protein 2 
1426617_a_at Ttyh1 tweety homolog 1 (Drosophila) 
Up-regulated in both 4F and 3F reprogramming 
1428209_at Bex4 brain expressed gene 4 
1452004_at Calca calcitonin/calcitonin-related polypeptide, alpha 
1442273_at Ccdc158 coiled-coil domain containing 158 
1417590_at Cyp27a1 
cytochrome P450, family 27, subfamily a, 
polypeptide 1 
1460454_at Glod5 glyoxalase domain containing 5 
1430238_at Got1l1 glutamic-oxaloacetic transaminase 1-like 1 
1434670_at Kif5a kinesin family member 5A 
1426255_at Nefl neurofilament, light polypeptide 
1416965_at Pcsk1n 
proprotein convertase subtilisin/kexin type 1 
inhibitor 
1434292_at Snhg11 
small nucleolar RNA host gene 11 (non-protein 
coding) 
1417426_at Srgn serglycin 
1421606_a_at Sult4a1 sulfotransferase family 4A, member 1 
1419289_a_at Syngr1 synaptogyrin 1 
1418743_a_at Tesc tescalcin 
1418744_s_at Tesc tescalcin 
1424351_at Wfdc2 WAP four-disulfide core domain 2 
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Table S2-2 Primers used for quantitative and semi-quantitative RT-PCR in 
Chapter Two. 
Primer Sequence 
Oct4 F CCAGAAGGGCAAAAGATCAA 
Oct4 R GCTCCTGATCAACAGCATCA 
Sox2 F ACCAGCTCGCAGACCTACAT 
Sox2 R CCCTCCCAATTCCCTTGTAT 
Nanog F AAGTACCTCAGCCTCCAGCA 
Nanog R GAAGTTATGGAGCGGAGCAG 
Fbxl15 F ACATTGCCTCCCGACACTAC 
Fbxl15 R GAAGGCAGGCAGATCTCAAG 
Utf1 F CGTCGCTACAAGTTCCTCAA 
Utf1 R CAGAGTGTCGGTGCTCGTAA 
Gapdh F CATGGCCTTCCGTGTTCCTA 
Gapdh R GCCTGCTTCACCACCTTCTT 
Mreg F GCGGCAGATCCGCAGGGAAG 
Mreg R CTCCCAGCTGGCGGGGAAGA 
Krt12 F GGCTCGCTGGCTGAAACCGA 
Krt12 R CTCCAGGCGAGCCTTGACGC 
Bex1 F TTCGGCAGCCCATCGCTCAC 
Bex1 R CGGGTCAGTGCTAACCGCCC 
 
 
  
                                                                                                                            
 
 
CHAPTER 3  KDM2B PROMOTES INDUCED PLURIPOTENT STEM CELL 
GENERATION BY FACILITATING GENE ACTIVATION EARLY IN 
REPROGRAMMING
#
 
 
3.1 Introduction 
Direct reprogramming from somatic cells to a pluripotent state can be achieved by 
introduction of defined transcription factors, such as Oct4, Sox2, Klf4 and c-Myc 
(Takahashi and Yamanaka 2006). The resultant iPS cells are molecularly and functionally 
similar to ES cells derived from the inner cell mass of a blastocyst (Hanna et al. 2010; 
Stadtfeld and Hochedlinger 2010). However, the process of iPS cell generation is highly 
inefficient, in terms of its frequency and the long latency prior to the establishment of 
pluripotency (Hanna et al. 2010; Stadtfeld and Hochedlinger 2010), due to some putative 
stochastic event(s) (Hanna et al. 2009; Yamanaka 2009). In the past several years, a 
number of factors that affect reprogramming efficiency through cell cycle dependent or 
independent mechanisms have been identified. For example, inhibition of the p53-p21 
pathway and the Ink4a/Arf locus increases the reprogramming efficiency and accelerates 
the reprogramming dynamics by affecting cell proliferation (Banito et al. 2009; Hanna et 
al. 2009; Hong et al. 2009; Kawamura et al. 2009; Li et al. 2009; Utikal et al. 2009); 
whereas, ectopic expression of Nanog enhance reprogramming presumably through 
epigenetic mechanism without changing cellular proliferation status (Hanna et al. 2009).  
                                                 
#
 Adapted from Liang G, He J, Zhang Y. 2012. Nat Cell Biol doi:10.1038/ncb2483. 
 
                                                                                                                            
48 
 
A recent study suggests that reprogramming from fibroblasts to iPS cells 
undergoes a series of transcriptional changes (Samavarchi-Tehrani et al. 2010). At the 
beginning, epithelial genes that alter the morphology of fibroblast to an ES cell-like state 
are first activated, followed by the activation of transcription factor Nanog and other 
pluripotent factors. After these waves of activation, mesenchymal genes are repressed, 
followed by the activation of “mature” pluripotent genes (Samavarchi-Tehrani et al. 
2010). Consistent with these sequential molecular events, factors facilitating 
mesenchymal-to-epithelial transition (MET), such as BMPs, Tgf-β inhibitors and miR-
200s, have been shown to be capable of promoting iPS cell generation (Ichida et al. 2009; 
Maherali and Hochedlinger 2009; Li et al. 2010; Samavarchi-Tehrani et al. 2010), 
indicating that activation of an transcription program during early stage of 
reprogramming is crucial for the establishment of pluripotency. However, how such a 
transcription program is activated is currently unknown. 
Given that cell fate reprogramming is essentially reprogramming of epigenetic 
states (Goldberg et al. 2007), it is not surprising that chemical inhibitors of epigenetic 
enzymes (Huangfu et al. 2008a; Mikkelsen et al. 2008; Shi et al. 2008a; Liang et al. 
2010), and certain chromatin-remodeling factors (Singhal et al. 2010) are able to promote 
iPS cell generation. Through studying epigenetic factors specifically enriched in ES cells, 
we found that Kdm2b (also named Jhdm1b and Fbxl10), an H3K36me2-specific 
demethylase, is able to facilitate iPS cell generation. This property is not dependent on its 
effect on cell proliferation, but relies on its demethylase and DNA binding activities. 
Further analysis demonstrates that Kdm2b enhances reprogramming by promoting the 
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expression of epithelial genes, whose activation is required for achieving pluripotency 
(Chen et al. 2010; Li et al. 2010; Redmer et al. 2011).  
3.2 Results 
Kdm2b promotes iPS cell generation  
To identify epigenetic factors that facilitate iPS cell generation, we focused on 
epigenetic factors enriched in ES cells. Kdm2b is one member of the Kdm2 protein 
family (Figure S3-1) capable of removing H3K36me2 (Tsukada et al. 2006; He et al. 
2008). Kdm2b isoform 1 (IF1, hereafter referred as Kdm2b) is highly expressed in ES 
cells compared to mouse embryonic fibroblasts (MEFs) (Figure 3-1A) and is 
progressively up-regulated during reprogramming by Oct4, Sox2 and Klf4 (OSK) (Figure 
S3-2). To explore its potential role in iPS cell generation, we constructed a doxycycline-
inducible lentiviral plasmid that expresses C-terminal Flag-tagged Kdm2b. Upon 
doxycyclin induction, Kdm2b is expressed about 50 times of the Kdm2b level in ES cells 
(Figure S3-3). When introduced into Oct4-IRES-GFP/Rosa26-M2rtTA MEFs together 
with the retroviral reprogramming factors OSK, it can increase Oct4-GFP+ colony 
numbers by 4−6 folds at days 12 and 16 of reprogramming (Figure 3-1B), indicating that 
Kdm2b is capable of enhancing OSK-mediated iPS cell generation.  
We next asked whether Kdm2b is able to promote iPS cell generation in the 
presence of c-Myc by introducing Kdm2b into the cocktail of OSK plus c-Myc (OSKM). 
Results shown in Figure 3-1C demonstrate that Kdm2b is capable of increasing Oct4-
GFP+ colonies numbers in the presence of c-Myc, indicating that Kdm2b likely 
facilitates iPS cell generation differently from c-Myc. By following the reprogramming 
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kinetics, we found that, although Kdm2b promotes iPS cell generation, it does not 
significantly shorten the latency time for the appearance of Oct4-GFP+ colonies, as the 
first Oct4-GFP+ colony appears around day 10 (OSK) or day 8 (OSKM) of 
reprogramming regardless whether Kdm2b is introduced to the reprogramming system 
(Figure 3-1D). This observation differs from cell cycle-based enhancement of iPS cell 
generation, including depletion of p53 and p21 (Hanna et al. 2009; Hong et al. 2009; 
Kawamura et al. 2009) and inhibition of Ink4a/Arf (Li et al. 2009; Utikal et al. 2009), 
which significantly shortens the latency time of iPS cell generation through promoting 
cell proliferation (Hanna et al. 2009). Therefore, Kdm2b enhances reprogramming likely 
by using a cell cycle-independent mechanism similar to Nanog overexpression (Hanna et 
al. 2009).  
To further confirm the role of Kdm2b in reprogramming, we introduced small 
hairpin RNA (shRNA) (He et al. 2008), which depletes the Kdm2b mRNA level by 
around 80% (Figure 3-1E), to the reprogramming cells co-transduced with OSK. We 
found that the reprogramming efficiency is reduced to half when shRNA against Kdm2b 
(Kdm2b-i) is introduced (Figure 3-1F), indicating that Kdm2b is required for optimal 
induction of iPS cells. Collectively, the above studies demonstrate that Kdm2b facilitates 
iPS cell generation. 
iPS cells generated in the presence of Kdm2b are pluripotent  
Next, we set out to characterize the Oct4-GFP+ iPS cells generated with OSK in 
the presence of exogenous Kdm2b. After 16–18 days of iPS cell induction, Oct4-GFP+ 
colonies were manually picked up and propagated into cell lines in the absence of 
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doxycyclin. The resulting cell lines exhibit typical ES cell morphology with Oct4-GFP 
expression (Figure 3-2A). These cells are positive for alkaline phosphatase (AP) activity 
and express ES cell markers SSEA-1, as well as pluripotent transcription factors Nanog 
and Sox2 (Figure 3-2B). RT-qPCR demonstrates activation of endogenous Oct4, Sox2 
and Nanog genes to a level similar to that in ES cells (Figure 3-2C). In contrast, the 
transgenes, including the retrovirus introduced Oct4, Sox2 and Klf4, and the lentiviral 
inducible Kdm2b, are mostly silenced in the iPS cell lines, as shown by semi-quantitative 
RT-PCR (Figure 3-2D). When implanted into immunodeficient mice, these iPS cells 
generated teratomas with tissues belonging to all three germ layers (Figure 3-2E). 
Importantly, these iPS cells are competent for chimera generation when injected into 
blastocystes (Figure 3-2F). These data support that the iPS cells generated in the presence 
of exogenous Kdm2b are pluripotent. 
Kdm2b facilitates iPS generation in an enzymatic activity-dependent and cell 
proliferation alteration-independent manner  
To understand how Kdm2b facilitates iPS generation, we attempted to determine 
the domains of Kdm2b important for this property. To this end, we carried out 
reprogramming with point mutations in the catalytic JmjC domain (Tsukada et al. 2006; 
He et al. 2008) and the DNA binding zinc finger-CXXC (ZF) domain (Voo et al. 2000; 
Blackledge et al. 2010). We first confirmed that both the mutants and wild-type (WT) 
Kdm2b are expressed at a similar level upon doxycyclin induction (Figure 3-3a). 
Consistent with Kdm2b’s enzymatic activity, doxycycline induced expression of WT and 
ZF mutant, but not the catalytic mutant, leads to a specific decrease of H3K36me2 levels 
(Figure 3-3A). Importantly, these three forms of Kdm2b display differential capacity in 
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enhancing iPS cell generation when introduced to the reprogramming system. Mutations 
on either JmjC or ZF abrogate the capacity of Kdm2b in promoting iPS cell generation 
(Figure 3-3B), indicating that both the demethylase activity and the DNA binding activity 
of Kdm2b are functionally important for its role in iPS cell generation. 
Previous studies have demonstrated a role for Kdm2b in promoting cell 
proliferation by repressing senescence (He et al. 2008; Pfau et al. 2008; Tzatsos et al. 
2009). To determine whether the capacity of Kdm2b in promoting iPS cell generation is 
solely mediated by promoting cell proliferation, we examined how ectopic expressions of 
Kdm2b affect cell proliferation in the context of OSK-mediated reprogramming. We 
found that although ZF domain of Kdm2b is critical for its role in promoting iPS 
generation, it is not required for its ability to promote cell proliferation as both the WT 
and the ZF mutant promoted cell proliferation to a similar level (Figure 3-3C). These data 
suggest that the ability of Kdm2b in enhancing cell proliferation is not sufficient for 
promoting iPS cell generation. To illustrate that the cell proliferation effect of Kdm2b is 
not a major contributor to its effect on reprogramming, we normalized the 
reprogramming efficiency by dividing the Oct4-GFP+ colony numbers with the total cell 
numbers in the reprogramming cell populations. Results presented in Figure 3-3D 
indicate that the presence of Kdm2b still increases reprogramming efficiency for more 
than 4 folds. Although the JmjC mutant also increases the reprogramming efficiency, it is 
only about half of the effects exhibited by the WT, while the ZF mutant completely loses 
the effect on enhancement. These analyses indicate that the demethylase activity and the 
DNA binding capacity of Kdm2b are essential for its function in promoting iPS cell 
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generation, and that cell proliferation promoted by Kdm2b is not a major contributing 
factor for its role in promoting reprogramming. 
To further ascertain that Kdm2b-mediated suppression of senescence is not a 
major contributor to its role in reprograming enhancement, we examine the transcript 
levels of Ink4a, Arf and Ink4b during Kdm2b-mediated reprogramming. We found that, 
Ink4a, but not Arf or Ink4b, is significantly downregulated by Kdm2b in the first 12 days 
of OSK reprogramming (Figure 3-4A). However, the protein level of Ink4a is less 
affected by Kdm2b, probably due to the stability of this protein (Figure 3-4B). To 
examine whether repression of this locus contributes to Kdm2b-mediated enhancement of 
reprogramming, we introduced shRNAs, that depleted Ink4a and Arf by more than 90% 
at mRNA and protein levels (Figure 3-4C, -D), to the reprogramming cells transduced 
with OSK and OSK plus Kdm2b. We found that, albeit the deficiency of Ink4a/Arf, 
Kdm2b is still able to increase Oct4-GFP+ colony numbers by 3–4 folds compared to 
OSK reprogramming, suggesting that the Kdm2b-mediated enhancement of iPS cell 
generation is largely independent of its role in downregulating Ink4a/Arf (Figure 3-4E). 
Consistent with previous finding that suppression of the senescence pathway generally 
promotes reprogramming (Banito et al. 2009; Li et al. 2009; Utikal et al. 2009), we also 
observed a great enhancement of reprogramming efficiency when Ink4a/Arf are depleted 
regardless whether Kdm2b is used (Figure 3-4E). Collectively, our data suggest that the 
ability of Kdm2b to suppress cellular senescence is not the major reason for its role in 
enhancing reprogramming.   
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Kdm2b functions early during the reprogramming process 
Given that the role of Kdm2b in suppressing senescence and/or promoting cell 
proliferation is not a major contributor, and that introduction of Kdm2b does not enhance 
expression of transduced reprogramming factors (Figure S3-4), we searched for 
alternative mechanisms. Previous studies suggest that reprogramming can be divided into 
stages with distinct molecular features (Brambrink et al. 2008; Stadtfeld et al. 2008; 
Samavarchi-Tehrani et al. 2010), and factors that promote iPS cell generation can 
function at different stages during reprogramming (Ichida et al. 2009; Silva et al. 2009; 
Sridharan et al. 2009a). Therefore, we attempted to first determine the time window at 
which Kdm2b enhances iPS generation. To this end, we added doxycyclin to induce the 
expression of Kdm2b for different durations and analyzed its effect on the efficiency of 
iPS cell generation. Compared with the OSK control, enforced expression of Kdm2b in 
the first 8 days constantly enhanced the reprogramming efficiency, and prolonged 
induction of Kdm2b does not further enhance iPS cell generation (Figure 3-5A, upper 
panels). As a complement, we also induced Kdm2b expression beginning at different 
days after the initiation of reprogramming and found that the increase in reprogramming 
efficiency is largely proportional to the length of the doxycyclin treatment (Figure 3-5A, 
lower panels). Together, these studies indicate that Kdm2b promotes iPS cell generation 
by functioning early during the reprogramming process.  
Kdm2b amplifies early gene activation during reprogramming  
To understand the effect of Kdm2b during reprogramming at the molecular level, 
we performed microarray studies on cells harvested at days 4, 8 and 12 during the OSK 
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reprogramming in the presence or absence of Kdm2b. This analysis revealed a total of 
418 probes that showed a minimum of 2-fold upregulation for at least one of the three 
selected time points, while 143 probes showed at least 2-fold downregulation (Figure 3-
5B). Hierarchical clustering of these probes revealed that the Kdm2b upregulated genes 
can be grouped into three distinct clusters (cluster I, II and III) based on the time of their 
activation. Cluster I consists of probes upregulated at days 8 and 12; cluster II consists of 
probes upregulated from days 4 to 12; and cluster III probes are only upregulated on day 
4 (Figure 3-5B). In contrast, Kdm2b downregulated genes are distributed more 
ambiguously in terms of their affected timing.  
Gene ontology analysis revealed that Kdm2b affected genes are exceptionally 
enriched for adhesion processes (p-value = 10
−10
 ~ 10
−12
). Other terms with a significant 
p-value (< 10
−3
) includes those related to cell morphology, development and epithelium-
related processes (Figure 3-5B). Of particular relevance, recent studies have 
demonstrated that reprogramming starts from activation of epithelial adhesion genes, 
which results in dramatic change in cell morphology and adhesion properties (Li et al. 
2010; Samavarchi-Tehrani et al. 2010). Consistent with the notion that Kdm2b functions 
early at the beginning of reprogramming, Kdm2b likely plays a role in regulating these 
early responsive genes during reprogramming. To explore this possibility, we compared 
the Kdm2b-affected genes with a list of “signature” genes (Figure S3-5) whose 
expressions are dynamically regulated at different stages of the reprogramming process  
(Samavarchi-Tehrani et al. 2010). We found that Kdm2b-affected genes include some 
early activated “signature” genes, such as the epithelial genes Cdh1, Cldn3, -4 and -7, 
Epcam, Esrp1 and Ocln, as well as pluripotent genes Nanog, Dppa5a and Tdgf1 (Figure 
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3-5D). Indeed all the previously identified early activated genes (Samavarchi-Tehrani et 
al. 2010) have enhanced expression in the presence of Kdm2b, while the late activated 
genes or the repressed genes are not significantly altered by Kdm2b (Figure S3-5). 
Therefore, Kdm2b appears to be involved in the activation of the early responsive genes 
during reprogramming. 
Given that Kdm2b exerts its effect till day 8 during reprogramming (Figure 3-5A), 
the gene expression changes observed at days 4 and 8 are likely to be direct or primary 
effect of Kdm2b, while those changed at days 8 and 12 are more likely due to secondary 
effect. To better understand these changes, we grouped the Kdm2b-affected genes based 
on timing of the effect and found that most of the upregulated genes at days 4 and 8 
continue to be upregulated at later time points (Figure 3-5E), while genes upregulated at 
days 8 and/or 12 are mostly not shared with the sets of genes activated at an earlier time 
points. Similarly, most downregulated genes at day 4 continue to be downregulated at 
later time points, while those downregulated at days 8 and 12 are mostly not shared with 
those downregulated at day 4 (Figure 3-5E). Such a gene distribution pattern prompts us 
to hypothesize that introduction of Kdm2b amplifies a putative reprogramming 
transcriptional cascade (see discussion).  
To probe into the potential difference among genes activated by Kdm2b at 
different time during reprogramming, we carried out gene ontology analysis of the 
different sections of genes in Figure 3-5E. We found that genes upregulated from days 4 
through 12 are enriched in adhesion molecules (Figure 3-5F), consistent with the notion 
that Kdm2b functions from the beginning in regulating cell adhesion during 
reprogramming. Interestingly, genes that are significantly upregulated at day 4 only are 
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enriched in regulation of adhesion; those upregulated at days 8 and 12 are enriched for 
developmental genes in addition to genes of adhesion molecules; and those only 
upregulated at day 12 are more enriched for developmental process (Figure 3-5f). Such 
changes in gene function implicates that a developmental-related transcription program is 
triggered sometime after an initial adhesion-related program during reprogramming. 
Based on the delayed onset of the activation of development-related transcription 
program, it is likely that its activation requires the complement of preceding transcription 
activation, at least, to a certain extent, hence very likely constituting a transcription 
cascade. Later we found that the timing of the switch in gene functions coincides with 
that of Nanog activation (Figure 3-6A). For the downregulated gene, only those 
downregulated at day 8 showed an enriched functionality in immune response (Figure 3-
5E), whose significance remains to be clarified.  
Next, we performed RT-qPCR to verify the upregulation of genes encoding for 
epithelial cell markers, such as Cdh1 (also known as E-cadherin), Crb3 and Epcam, as 
well as desmosomes components Dsg2 and Dsp (Figure 3-6A, -B). Enhanced expression 
of these genes starts at day 4 (Figure 3-6B), and more obviously affected at days 8 and 12 
(Figure 3-6A, -C). We also note that genes activated earliest at day 4 include those 
encodes transcription factors with a strong indication functioning in adhesion and 
development, including Irf6, which is important for cleft palate (Richardson et al. 2009; 
Thomason et al. 2010), and Insm1, which plays a role in pancreatic  and neuronal 
development (Gierl et al. 2006; Mellitzer et al. 2006; Farkas et al. 2008). Interestingly, 
these genes are also upregulated by OSK and introduction of Kdm2b further augments 
their activations (Figure 3-6A, -B). The function of these early responsive genes in 
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reprogramming remains to be characterized. Furthermore, the expression levels of 
pluripotent genes, such as Nanog and Tdgf1, are also enhanced by Kdm2b at days 8 and 
12 of induction, but not at day 4 (Figure 3-6A, -B). Since Kdm2b functions at the initial 8 
days of OSK reprogramming (Figure 3-5A), these pluripotent genes are likely to be 
regulated by Kdm2b indirectly.  
In addition to adhesion and pluripotent genes, we also examined the expression of 
mesenchymal-specific transcription factors, which has been previously shown to be 
downregulated following the activation of Nanog and other pluripotent genes 
(Samavarchi-Tehrani et al. 2010). We observed a mild downregulation of Snai1, Snai2, 
Zeb1 and Zeb2 at days 8 and/or day 12 (Figure S3-5A) although their downregulation is 
less than 2 folds and consequently not picked up by the microarray analysis (Figure 3-
5D). Finally, we did not observe activation of endogenous Oct4 and Sox2 during the first 
12 days of reprogramming (Figure S3-5B), consistent with the fact that even in the case 
of Kdm2b-assisted reprogramming, only a very small fraction of the starting cells gained 
pluripotency in the 12 days of reprogramming monitored (Figure 3-1B) and hence their 
existence could not be reflected at mRNA level in the bulk population of reprogramming 
cells. Collectively, data presented above suggest that Kdm2b facilitates activation of 
genes related to epithelial adhesion, which may in turn activate downstream genes 
including pluripotent genes. Thus, it seems sensible that Kdm2b promotes iPS cell 
generation by facilitating the initiation of a putative transcription cascade. 
Since mutations in JmjC domain and ZF domain abrogate the capacity of Kdm2b 
in promoting iPS cell generation, we asked whether these mutations affect the capacity of 
Kdm2b to argument the activation of these genes. RT-qPCR and Western blot analysis 
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demonstrate that both mutations abolish the ability of Kdm2b to activate Cdh1 and 
Epcam (Figure 3-6D, -E), as well as subsequent activation of Nanog (Figure 3-6D). 
These results support a link between the ability of Kdm2b in activating these genes and 
its role in facilitating iPS cell generation, consistent with the notion that Kdm2b enhances 
iPS cell generation by facilitating early gene activation. 
Kdm2b acts in concert with the key reprogramming factors in early gene 
activation  
To understand how Kdm2b facilitates activation of early reprogramming genes, 
we asked whether Kdm2b activates these genes alone or in concert with the key 
reprogramming factors. To this end, we introduced individual factors and different factor 
combinations into MEFs and examined their effects on the expression of early responsive 
epithelial genes, such as Cdh1, Crb3 and Epcam, as well as the later activated Nanog. We 
found that, overall when any of the OSK factor is omitted, activation of these genes is 
either greatly compromised or completely abolished even in the presence of Kdm2b 
(Figure 3-6F). This observation is consistent with the fact that Kdm2b cannot replace any 
of the OSK in iPS cell generation (data not shown). However, we note that Kdm2b alone 
does exhibit a 5-fold activation on Cdh1 gene when compared to non-transduced MEF 
cells. Nevertheless, this activation appears to be minor (5%) when compared to the 
activation by OSK (Figure 3-6F). Similar to previous report (Li et al. 2010), transduction 
of Klf4 alone can partially activate Cdh1 comapared to OSK transduction. Its activation 
can be further boosted when Kdm2b is combined with Klf4. (Figure 3-6F). For Crb3, 
Epcam and Nanog, Kdm2b barely activate them in the absence of any the OSK (Figure 3-
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6F). Based on these results, we conclude that Kdm2b amplifies gene activation through 
cooperating with the key reprogramming factors OSK. 
Kdm2b binds to and regulates the H3K36me2 level of the promoter of early 
activated genes 
To determine whether Kdm2b directly contributes to the activation of the early 
responsive genes, we asked whether Kdm2b binds to these genes. Taking advantage of 
the Flag epitope on the Kdm2b constructs, we performed chromatin immunoprecipitation 
(ChIP) analysis using cells at day 4 of reprogramming. This analysis demonstrates that 
Flag-Kdm2b is enriched in the promoter region of the early activated genes, including 
Cdh1, Epcam, Dsg2, Dsp and Irf6; however, no enrichment is detected at the Nanog 
promoter, consistent with the notion that Kdm2b contributes to Nanog activation 
indirectly (Figure 3-7A). We also profiled the localization of exogenous Kdm2b at the 
Cdh1 locus, finding that Kdm2b localizes from the promoter to the middle of the gene 
body, but not in the region proximal to 3’ end or upstream beyond the promoter (Figure 
3-7B, C).  Parallel ChIP experiments demonstrate that the level of H3K36me2 at the 
promoter of Cdh1, Dsp and Irf6 is decreased upon the introduction of Kdm2b (Figure 3-
7D), but H3K4me2, an irrelevant modification to Kdm2b enzymatic activity, remains 
unchanged, consistent with the fact that Kdm2b preferentially removes H3K36me2 (He et 
al. 2008). These results support the notion that Kdm2b contributes to the activation of 
early responsive genes by binding to and demethylting H3K36me2 on their promoters.  
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Enhanced early gene activation mediates the effect of Kdm2b in 
reprogramming 
Epithelial genes, which are activated early (Li et al. 2010; Samavarchi-Tehrani et 
al. 2010) and whose activation is enhanced by Kdm2b during reprogramming, are 
subjected to repression by Tgf-β signaling (Heldin et al. 2009). To demonstrate that 
increased expression of these genes contributes to the increased reprogramming 
efficiency by Kdm2b, we perform reprogramming by OSK plus Kdm2b in the presence 
of Tgf-β. We found that, upregulation of epithelial genes, such as Cdh1 and Epcam, by 
Kdm2b are abrogated upon Tgf-β treatment (Figure 3-8A). Importantly, Kdm2b-
enhanced iPS generation is also abrogated by Tgf-β (Figure 3-8B), consistent with the 
notion that Kdm2b-enhanced expression of the epithelial genes contributes to its effect on 
reprogramming. To directly address the role of these epithelial genes in mediating 
Kdm2b-enhanced reprogramming, we focused on Cdh1, one of the epithelial genes 
directly regulated by Kdm2b. We generated three shRNAs that efficiently deplete Cdh1 
(Figure 3-8C, -D) and asked whether the effect of Kdm2b-enhanced OSK reprogramming 
is affected by these shRNAs. Results shown in Figure 3-7E demonstrate that Kdm2b-
mediated enhancement of reprogramming is reduced by 60 – 90% upon Cdh1 depletion, 
suggesting that Cdh1 is one of the key downstream targets that mediating Kdm2b’s effect 
in reprogramming. We also tested whether enforced expression of Cdh1 can enhance 
OSK-mediated reprogramming; however, consistent with previous reports (Li et al. 2010; 
Redmer et al. 2011), we found that adding Cdh1 into the reprogramming factor cocktails 
failed to enhance iPS cell generation, indicating that overexpressing Cdh1 alone is not 
sufficient to mimic the effect of Kdm2b. Nevertheless, our data demonstrates that Cdh1, 
at least, in part, mediates Kdm2b’s effect on reprogramming. 
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3.3 Discussion 
Kdm2b promotes reprogramming independent of its effect on cell 
proliferation 
Despite cellular senescence is a “roadblock” for reprogramming (Li et al. 2009; 
Utikal et al. 2009), and that Kdm2b is capable of suppressing senescence (He et al. 2008; 
Tzatsos et al. 2009), several lines of evidence suggest that Kdm2b promotes iPS 
generation is largely independent of its role in senescence and/or cell proliferation. First, 
although Kdm2b mildly increases cell proliferation during reprogramming (Figure 3-3C), 
when the proliferation effect is subtracted, Kdm2b still exhibits more than 4-fold increase 
in reprogramming efficiency (Figure 3-3D). Second, although an intact ZF domain is 
require for Kdm2b to promote iPS cell generation, mutation on this domain does not alter 
its ability to stimulate cell proliferation, suggesting that the roles of Kdm2b in promoting 
proliferation and iPS cell generation are independent and separable. Third, when 
Ink4a/Arf, the key senescence regulators and documented targets of Kdm2b (Tzatsos et al. 
2009), are depleted, Kdm2b is still capable of promoting iPS generation (Figure 3-4E), 
indicating that the ability of Kdm2b in antagonizing senescence is not a major contributor 
for its role in promoting iPS cell generation. Lastly, Kdm2b does not significantly shorten 
the latency time from induction to the appearance of first Oct4-GFP+ colony (Figure 3-
1d), which is consistent with the reprograming kinetics of cell cycle-independent 
enhancement of reprogramming (Hanna et al. 2009).  
While our manuscript is under review, Pei and colleagues published data 
demonstrating that Kdm2b (Jhdm1b in their report) greatly enhances iPS cell generation 
in the presence of vitamin C and suggest that the effect of Kdm2b is mediated through 
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promoting cell cycle progression and activation of microRNA cluster 302/367 (Wang et 
al. 2011). However, most of the mechanistic studies are performed in the presence of 
both vitamin C, and therefore, the specific contribution from Kdm2b to iPS cell 
generation is not addressed. Indeed, the same group previously found that treatment of 
vitamin C is capable of alleviating the blockage of cell cycle progression imposed by 
p53-p21(Esteban et al. 2010). Since vitamin C has more pronounced effect on iPS cell 
generation than Kdm2b (Wang et al. 2011), it is possible that the effect of vitamin C on 
cell cycle progression might mask the effect of Kdm2b and consequently the contribution 
of Kdm2b to iPS cell generation might be overshadowed.  
A transcription cascade model for gene regulation in reprogramming 
By analyzing the gene expression changes within or immediately after the 
functioning time window of Kdm2b, we found that exogenous Kdm2b enhances the 
expression of a set of early activated genes during reprogramming (Figure 3-5D and 
Figure S3-4). The enhanced expression of epithelial genes (Cdh1, Epcam and etc.) and 
other uncharacterized genes (Irf6 and Insm1) takes place in the functioning time window 
of Kdm2b (Figure 3-5A, -6A, -6B). Following this first wave of activation, the 
expression of Nanog and other pluripotency factors are upregulated (Figure 3-6A, B) 
concomitant with enrichment of developmental genes in the upregulated gene group 
(Figure 3-5F). Meanwhile, some mesenchymal genes, whose downregulation follows 
Nanog activation (Samavarchi-Tehrani et al. 2010), begin to display magnified 
downregulation in the presence of Kdm2b (Figure S3-5A). Soon after Nanog activation 
(day 8; Figure 3-6A), first Oct4-GFP positive colonies are observed at day 10 (Figure 3-
1D). The observation that Kdm2b amplifies these sequential transcription events 
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prompted us to propose a transcription cascade model to explain how Kdm2b might 
contribute to reprogramming (Figure 3-8F). We propose that Kdm2b facilitates initial 
gene activation that occurs on the epithelial genes, causing an amplified transcription 
cascade, which in turn enhances the activation of pluripotent genes such as Nanog, 
eventually resulting in an increase in reprogramming efficiency (Figure 3-8F).  
This model is consistent with previous observation that Tgf-β inhibitors induce 
Nanog expression and enhance reprogramming (Ichida et al. 2009; Maherali and 
Hochedlinger 2009) as Tgf-β signaling inhibits epithelial gene expression (Heldin et al. 
2009; Li et al. 2010) and suppression on Tgf-β potentially helps activation of epithelial 
genes. It also agrees with the notion that Nanog is not required for initiating 
reprogramming but plays a key role in driving the “pre-iPS” cells to pluripotency (Silva 
et al. 2009). Uncovering the potential links between transcription events is crucial for 
attesting the transcription cascade model. 
Kdm2b facilitates early gene activation in reprogramming 
Our study revealed that Kdm2b promotes activation of early responsive genes at 
the beginning of the reprogramming process (Figure 3-5, 6). Although the details of how 
Kdm2b contributes to the activation of these genes need to be revealed, our studies 
provide a few clues. First, upregulation of these early-activated epithelial genes is not due 
to a decrease in the levels of mesenchymal transcription factors as downregulation of 
mesenchymal transcription factors takes place after the activation of epithelial genes 
(Figure S3-5A). Secondly, we found that the ability of Kdm2b in promoting the 
activation of early reprogramming genes is dependent on the presence of OSK in the 
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reprogramming cocktail (Figure 3-6F). This is consistent with our observation that 
Kdm2b cannot replace any of the OSK for iPS cell generation under our reprogramming 
conditions (data not shown). Finally, we demonstrate that Kdm2b binds to the promoter 
of some of the activated epithelial genes and maintains H3K36me2 at a lower level 
(Figure 3-7A, D) supporting a direct role for Kdm2b in regulating expression of these 
genes. How Kdm2b is recruited to its targets and how Kdm2b promotes the activation of 
epithelial genes remains to be determined. 
H3K36 methylation has been mostly linked to transcriptional elongation and the 
studies are mostly carried out in yeast. Therefore, the role of promoter H3K36 
methylation in mammalian cells is largely unknown. A recent genome-wide study in 
mouse ES cells revealed that Kdm2a, a paralog of Kdm2b, binds to nonmethyl-CpG 
island promoters and depletes H3K36me2 at these promoters (Blackledge et al. 2010). 
Given that Kdm2b also contains a ZF (CXXC) domain, a nonmethyl-CpG binding 
domain, we anticipate that Kdm2b should also localize to the nonmethyl-CpG islands. In 
addition to devoid of H3K36me2, nonmethyl-CpG island promoters are also enriched for 
H3K4me3 installed by Cfp1-mediated recruitment of Setd1 (Thomson et al. 2010), as 
well as the 5-methylcytosine oxidase Tet1 (Wu et al. 2011b). Since all these chromatin 
features are linked to gene activation, it is not surprising that Kdm2b is involved in gene 
activation in our study. It is possible that binding of Kdm2b to nonmethyl-CpG promoters 
eliminates H3K36me2, which may facilitate OSK-mediated gene activation by 
establishing a platform for cofactor recruitment. Such a scenario explains why Kdm2b 
can promote gene activation (Figure 3-5, 6) and facilitate OSK-directed reprogramming 
(Figure 3-1) but fails to substitute for any of OSK (data not shown). Future studies should 
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reveal the molecular mechanisms underlying how demethylation of H3K36me2 
contributes to gene activation. 
3.4 Materials and methods 
Plasmids and virus preparation 
Mouse Kdm2b (isoform 1) were amplified from cDNA, fused with a C-terminal 
Flag tag, and cloned into a doxycyclin inducible lentiviral vector pTYF-TRE. The JmjC 
(H211A, D213A) and ZF (C573A C576A C579A) mutants were constructed by 
mutagenesis PCR and confirmed by sequencing. Target sequences of control shRNA and 
shRNAs against Kdm2b (He et al. 2008), Ink4a/Arf and Cdh1 are described in Table S3-
1. These shRNAs were expressed in lentiviral plasmid pTY-U6-Pgk-Puro.  Lentivirus 
was prepared by cotransfection of pTY/pTYF plasmids with pHP, pHEF1α-VSVG and 
pCEP4-Tat into 293T cells, and harvested at 24, 36 and 48 hours after transfection. Viral 
supernatant was filtered through 0.45-μm membrane and concentrated by spin column 
before applied to MEFs. Retroviral plasmids pMXs-Oct4, Sox2, Klf4 and c-Myc were 
obtained from Addgene, and retrovirus was prepared as previously described (Liang et al. 
2010).  
MEF derivation and iPS cell generation 
MEFs for iPS cell generation were prepared from E13.5 embryos of Oct4-IRES-
GFP/Rosa26-M2rtTA double knock-in mice. To derive iPS cells, MEFs at the first 2 
passages were seeded onto 6-well plates at a density of 1×10
5
 cells per well, 16 h before 
viral infection. Two doses of retrovirus and/or one dose of lentivirus was applied within 
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48 hours in the presence of polybrene (10 μg/ml). 24 hours after the second retroviral 
transduction, the virus supernatant was withdrawn and the day was designated as day 0 
post-transduction. Subsequently, iPS cells were induced for 12−18 days in mouse ES cell 
medium (DMEM with 15% FBS, non-essential amino acid, GlutaMax, sodium pyruvate, 
β-mercaptoethanol, penicillin/streptomycin and 1,000 U/ml leukemia inhibitory factors) 
in the presence of doxycyclin (1 μg/ml). If indicated, Tgf-β treatment was carried out by 
applying Tgf-β1 (R&D Systems) at 2 ng/ml. Oct4-GFP+ colonies were counted on 
selected days from day 6 to day 18. Reprogramming efficiency was presented as the 
number of Oct4-GFP+ colonies derived from 1×10
5 
MEFs. Relative reprogramming 
efficiency over a control induction is also used in some cases. At day 18, Oct4-GFP+ 
colonies were manually picked, trypsinized and seeded onto mitomycin C-treated feeder 
MEF cells. The derived iPS cell lines were propagated in mouse ES cell medium in the 
absence of doxycyclin for at least 8 passages before being characterized.  
Cell staining, teratoma assay and chimera generation 
For immunofluorescent staining, antibodies against SSEA-1 (Chemicon 
mAB4301, clone MC-480), Nanog (Bentyl, IHC-00205) and Sox2 (Millipore, AB5603) 
are applied at a concentration of 1:500, 1:250 and 1:1000, respectively. AP staining was 
carried out with AP detection kit (Millipore). Teratoma analysis was performed as 
previously reported(Liang et al. 2010). For generation of chimeric mice, twelve week old 
Albino B6 (C57Bl/6J-Tyr<c-2J>) female mice were stimulated to superovulation by 
injected with pregnant mare serum gonadotropin (2.5 IU) followed by administration of 
human chorionic ganadotropin (5 IU) 47 hours later. The female mice were subsequently 
mated with Albino B6 stud males and blastocysts were harvested on gestation day 3.5. 
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On the day of microinjection, iPS cells (line 8 and 17) were rinsed twice with PBS, 
dissociated with 0.05% trypsin, washed once with and then resuspended in Knockout 
DMEM supplemented with 15% FBS. Each blastocyst was injected with 10−15 iPS cells 
using a piezo impact micromanipulator. Injected embryos were then implanted into the 
uterus of pseudopregnant Swiss Webster recipient females.  
RT-PCR and Western blotting 
Quantitative and semi-quantitative RT-PCR was carried out using primers in 
Table S3-2.  Western blotting was performed using antibodies against Arf (Santa Cruz sc-
32748, clone 5-C3-1, 1:200), Cdh1 (Cell Signal 3195, clone 24E10, 1:1000), Epcam 
(Abcam ab32392, clone E144, 1:500), Flag (Sigma F1804, clone M2, 1:5000), histone 
H3 (Abcam ab1791, 1:5000), H3K4me2 (Active Motif 39141, 1: 1000), H3K36me1 
(Abcam ab9048, 1:1000), H3K36me2 (Tsukada et al. 2006) (1:1000), H3K36me3 
(Abcam ab9050, 1: 1000), Ink4a (Santa Cruz sc-1207, 1:200) and α-tubulin (Sigma 
T6199, clone DM1A, 1:2000).  
Microarray analysis 
RNA samples were extracted from cells transduced with OSK or OSK plus 
Kdm2b at post-transduction day 4, 8 and 12. The reverse transcription and hybridization 
procedure was carried out as previously described (Liang et al. 2010). The microarray 
data were analyzed with GeneSpring software and are available in ArrayExpress database 
(http://www.ebi.ac.uk/arrayexpress/) with accession number E-MEXP-3433. 
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Chromatin Immunoprecipitation (ChIP) 
Cells transduced with OSK plus Flag-tagged Kdm2b were harvested for ChIP at 
post-transduction day 4. ChIP was performed using Imprint ChIP Kit (Sigma) according 
to the manufacturer’s instruction. Chromatin was prepared by sonication at 4°C on 
Bioruptor 300 (Diagenode) with high magnitude for 10 cycles with 30 seconds on and 30 
seconds off. For each precipitation reaction, chromatin from 2×10
5
 cells was applied to a 
Stripwell pre-bound with antibodies against Flag (Sigma F1804, clone M2), H3K36me2 
(Tsukada et al. 2006), H3K4me2 (Active Motif 39141) or mouse IgG. If necessary, 
immunoprecipitated and purified DNA fragments were subjected to amplification using 
Whole Genome Amplification Kit (Sigma). Immunoprecipitated or amplified DNA was 
analyzed by quantitative PCR using primers listed in Table S3-3. 
Standard Error Reporting 
Data presented with error bars were collected from samples from at least two 
independent preparations. The number of preparations (n) for each experiment is denoted 
in the figure legend. Error bars reported represent standard error of the mean.  
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Figure 3-1 Kdm2b promotes iPS cell generation.  
(A) Isoform 1 (IF1) of Kdm2b is highly expressed in mouse ES cells. RT-qPCR analysis 
of the expression levels of Kdm2a and different isoforms of Kdm2b (IF1, IF2 and IF3) in 
mouse ES cells (ESC) and embryonic fibroblasts (MEF). Expression levels are 
normalized to Gapdh and compared to the expression level in MEF. n = 2. (B) Kdm2b 
increases the efficiency of iPS cell generation when co-introduced with Oct4, Sox2 and 
Klf4 (OSK). The efficiency is represented by the number of Oct4-GFP+ colony counted 
at post-transduction days 12 and 16 from 1×10
5
 starting MEFs. n = 3. (C) Kdm2b 
increases the reprogramming efficiency in the presence of c-Myc. Shown are numbers of 
Oct4-GFP+ colony at day 12 reprogrammed by OSK plus c-Myc (OSKM) in the 
presence or absence of Kdm2b. n = 3. (D) The reprogramming kinetics from day 6 to day 
16 using different combinations of reprogramming factors. n = 3. (E) RT-qPCR analysis 
of the knock-down efficiency of Kdm2b. The results were normalized to the Gapdh level 
and shown as relative to the control shRNA treatment (Control-i). n = 2. (F) Knockdown 
of Kdm2b reduced OSK-mediated reprogramming efficiency. Oct4-GFP+ colony 
numbers at days 14 and 18 are shown for OSK reprogramming with control (Control-i) or 
Kdm2b knockdown (Kdm2b-i). n = 2.  
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Figure 3-2 iPS cells generated by enforced expression of OSK plus Kdm2b are 
pluripotent.  
 (A) The morphology and Oct4-GFP expression of a representative iPS cell line derived 
from Kdm2b-assisted reprogramming. Scale bar, 200 μm. (B) Alkaline phosphatase (AP) 
activity and immunostaining of ESC markers (SSEA-1, Nanog, and Sox2) of a selected 
iPS cell line. Scale bar, 200 μm. (C) Activation of endogenous Oct4, Sox2 and Nanog in 
iPS cells derived from reprogramming by OSK plus Kdm2b. RT-qPCR were carried out 
on RNA samples harvested from MEF, ESC and selected iPS cell (iPSC) lines. (D) 
Silencing of retroviral transgenes pMXs-Oct4, -Sox2 and -Klf4 and lentiviral inducible 
pTYF-TRE-Kdm2b in the absence of doxycyclin in selected iPS cell lines. The RNA 
sample from doxycyclin-treated Oct4-IRES-GFP/Rosa26-M2rtTA MEFs introduced with 
the four transgenes serves as positive control (Control). (E) Representative pictures show 
the presence of gut-like cavities (endoderm), muscle tissues (mesoderm) and neural 
rosettes (ectoderm) in teratoma derived from iPS cells reprogrammed by OSK plus 
Kdm2b. Scale bar, 100 μm. (F) iPS cells generated in the presence of Kdm2b are 
competent in chimera mice generation. Shown are chimera mice derived from two 
representative iPS cell lines (iPSC8 and 17). 
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Figure 3-3 Kdm2b facilitates iPS cell generation in a JmjC and ZF domain-
dependent manner.  
(A) Western blot analysis demonstrates equal expression of wild-type and mutant Kdm2b 
with differential effects on global H3K36me2 levels. Lentivirus carrying doxycyclin 
inducible wild-type and mutant Kdm2b were respectively transduced into MEFs that 
constitutively expresses the transactivator rtTA. Expression of the constructs was induced 
by addition of doxycyclin (1 μg/ml).  Western blotting shows the equal expression levels 
of the various Kdm2b forms as well as their effects on histone modifications. Tubulin and 
histone H3 serves as a loading control. (B) Mutations on JmjC or ZF domain of Kdm2b 
abrogate its effect on iPS generation. Shown are Oct4-GFP+ colony numbers counted at 
days 12 and 16 reprogrammed using OSK, OSK plus wild-type Kdm2b and its JmjC and 
ZF mutant. n = 2. (C) The effect of Kdm2b on proliferation is dependent on its enzymatic 
activity, but independent of its ZF domain. Cell numbers are monitored for 12 days of 
reprogramming by OSK, and OSK plus WT and mutant Kdm2b. n = 2. (D) Relative 
reprogramming efficiency independent of the cell proliferation effect. The Oct4-GFP+ 
colony numbers in panel B were divided by the total cell numbers in panel c, and the 
results were all compared to OSK reprogramming and shown as the relative 
reprogramming efficiency. n = 2. 
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Figure 3-4 Kdm2b promotes iPS cell generation independently of Ink4a/Arf.  
(A) RT-qPCR analysis of the expression of Ink4a, Arf and Ink4b in Kdm2b-facilitated 
reprogramming. RNA samples were harvested from MEF, iPSC and cells at day 4 (D4), 8 
(D8) and 12 (D12) during reprogramming by OSK (−) and OSK plus Kdm2b (+). All the 
qPCR results were normalized to the expression of Gapdh and compared to the sample in 
the absence of Kdm2b (−) at D4. n = 2. (B) Western blot analysis shows the protein level 
of Ink4a and Arf in Kdm2b-facilitated reprogramming at D4 and D8. Protein extracts 
from the reprogramming cell samples in panel A, as well as MEFs, were used. Tubulin 
serves as a loading control. (C) RT-qPCR analysis demonstrates depletion of Ink4a and 
Arf transcript by introduction of shRNA against Ink4a/Arf. n = 2. (D) Western blot 
analysis demonstrates efficient depletion of Ink4a and Arf by shRNA against Ink4a/Arf. 
(E) Kdm2b remains its capacity to enhance reprogramming upon Ink4a and Arf depletion. 
Oct4-GFP+ colony number at day 16 for OSK or OSK plus Kdm2b reprogramming with 
or without Ink4a/Arf knock- down. n = 2. 
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Figure 3-5 Kdm2b exerts its effect from the beginning of reprogramming process 
and facilitates gene activation in early stage of reprogramming. 
(A) Kdm2b functions to promote iPS cell generation from the beginning of 
reprogramming process. Oct4-IRES-GFP/Rosa26-rtTAM2 MEFs were transduced with 
retroviral OSK and lentiviral Kdm2b driven by a doxycyclin inducible promoter. After 
transduction, doxycyclin (Dox) was applied to (red bars, left panels) or omitted from 
(grey bars) the cell cultures during the initial 12 days of reprogramming. Oct4-GFP+ cells 
were counted at day 12 and reprogramming efficiencies (green bars, right panels) are 
compared to that reprogrammed by OSK, which is set to 1. n = 2. (B) Hierarchical 
clustering of genes whose expression are significantly affected by the addition of Kdm2b 
into the reprogramming cocktail. The expression changes of the selected probes revealed 
by microarray analysis are at least 2 folds, and the changes occur at least in one of the 
three time points (days 4, 8 and 12). The heat map was derived via Pearson correlation 
coefficient from data of two biological replicates. Genes upregulated or downregulated 
by Kdm2b constitute two distinct clusters, with the upregulated genes subdivided into 
three groups (I, II and III) based on their time of activation. (C) Gene ontology analysis 
for all the genes identified in panel B. All the presented terms are above the p-value of 
1×10
−3
. (D) Venn diagram showing the common genes of Kdm2b-affected genes (panel 
A) and the previously identified signature reprogramming genes. Ten genes, which are 
represented by 12 probes in the microarray, are shown in the box. (E) Venn diagram 
showing the distribution of Kdm2b-affected probes at different time of reprogramming. 
(F) Gene ontology analysis for biological processes for different sections in panel E. The 
sections without any term enriched above the p-value of 1×10
−3
 are omitted.  
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Figure 3-6 Kdm2b directly activates early responsive genes in reprogramming.  
(A) RT-qPCR analysis verifying genes upregulated at different time points in Kdm2b-
facilitated reprogramming. RNA samples were extracted from MEF, iPSC and cells at 
day 4 (D4), 8 (D8) and 12 (D12) during reprogramming by OSK (−) and OSK plus 
Kdm2b (+). The qPCR results were normalized to Gapdh and compared to the samples in 
the absence of Kdm2b (−) at D4. n = 2. (B) Epithelial gene expression amplified by 
Kdm2b at the earliest time point. Expression data from panel A were rescaled to manifest 
the enhancement by introducing Kdm2b into the OSK cocktail (−) at day 4 (D4). The 
expression of OSK reprogramming (+) is set to 1. n = 2. (C) Western blot analysis 
demonstrates upregulation of Cdh1 and Epcam by Kdm2b. Protein extracts from the 
reprogramming cell samples in panel a, as well as MEFs and ESCs, were used. Tubulin 
serves as a loading control. (D) RT-qPCR analysis demonstrates that Kdm2b-enhanced 
activation of Cdh1, Epcam and Nanog depends on its JmjC and ZF domains. The analysis 
is performed at day 12 of reprogramming with cells reprogrammed by OSK, or OSK plus 
wild-type Kdm2b (WT), its JmjC or ZF mutants. All the qPCR results were normalized to 
Gapdh and compared to the OSK reprogramming. n = 2. (E) Western blot analysis of 
Cdh1, Epcam and tubulin with protein extract from the reprogramming cell samples in 
panel C. (F) Kdm2b cooperate with Oct4, Sox2 and/or Klf4 in transcription activation. 
RT-qPCR analysis of the expression of Cdh1, Crb3, Epcam and Nanog in MEF cells 
transduced with individual factors of Kdm2b, Oct4 (O), Sox2 (S) and Klf4 (K), as well as 
different factor combinations. RNA samples were harvested at post-transduction day 12. 
The qPCR results were first normalized to Gapdh and then compared to the sample 
transduced by OSK. n = 2.   
                                                                                                                            
80 
 
  
                                                                                                                            
81 
 
Figure 3-7 Kdm2b localizes on and demethylates the promoter region of early 
activated genes.  
(A) Chromatin immunoprecipitation (ChIP) analysis demonstrates that Kdm2b directly 
binds to the promoters of early activated genes. ChIP using anti-Flag antibody and IgG 
were performed with cells harvested at day 4 of reprogramming using OSK plus Flag-
tagged Kdm2b. The qPCR results were compared to IgG controls. n = 2. (B) Diagram of 
Cdh1 locus illustrating the locations of amplicons relative to the transcription start site 
(arrow) and transcribed sequence (gray box). (C) Kdm2b localizes from the promoter 
region to the middle of gene body at the Cdh1 locus. ChIP was prepared and the results 
shown as panel A. n = 2.  (D) ChIP analysis demonstrates reduction of H3K36me2 level 
correlates with Kdm2b binding to the early activated genes. ChIP using anti-H3K36me2 
and H3K4me2 were performed with OSK or OSKKdm2b-introduced cells harvested at 
day 4. The results for H3K36me2 and H3K4me2 were normalized to IgG. H3K4me2, a 
modification irrelevant to the enzymatic activity of Kdm2b, serves as a control. n = 2.  
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Figure 3-8 Inhibition of the expression of early-activated genes compromises the 
capacity of Kdm2b to enhance iPS cell generation.  
(A) Upregulation of early activated genes in reprogramming by Kdm2b is abrogated by 
administration of Tgf-β. RNA samples were harvested from reprogramming cells with 
indicated treatments at day 12. n = 2. (B) The capacity of Kdm2b to increase iPS cell 
generation efficiency is negated by Tgf-β. Oct4-GFP+ colony numbers were calculated at 
day 16 of reprogramming. n = 2. RT-qPCR (C) and Western blotting (D) confirmation of 
Cdh1 depletion. RNA and protein extracts are harvested from ES cells transduced with 
shRNA against Cdh1 (Cdh1-i) or control shRNA (Control-i). (E) Inhibition of Cdh1 by 
shRNA compromises Kdm2b-mediated enhancement of iPS cell generation. Shown are 
Oct4-GFP+ colony numbers at day 16 of reprogramming. n = 2. (F) Transcription 
cascade model explaining how Kdm2b enhances iPS cell generation. Introduction of 
Kdm2b into the reprogramming cocktail leads to upregulation of epithelial genes that are 
activated early during reprogramming, which in turn causes an amplified transcription 
cascade that enhances the activation of Nanog and the generation of iPS cells.   
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Figure S3-1 Diagram of domain structure for the Kdm2 family members.  
The Kdm2 family includes two members, Kdm2a and Kdm2b, with the latter having 
three isoforms (IF1, IF2 and IF3). The IF1 of Kdm2b is the longest isoform; IF2 lacks the 
Jumonji-C domain (JmjC) compared to IF1 and IF3; and IF3 is only slightly shorter than 
IF1 on the N-terminus. The N-terminuses of IF2 and IF3 are distinct from IF1 due to 
alternative transcription start sites. Both the IF1 and IF3 of Kdm2b share all the 
functional domains with Kdm2a, including JmjC domain, zinc finger-CXXC (ZF) 
domain, plant homeo domain (PHD), F-box domain (Fbox) and three runs of leucine-rich 
repeats (LRR). The number of amino acids (AA) for each protein is indicated in the 
figure. 
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Figure S3-2 Induction of Kdm2b in reprogramming and ectopic expression of 
Kdm2b.  
(A) Induction of endogenous Kdm2b isoform 1 (IF1) during OSK reprogramming. 
Samples from OSK reprogramming at post-transduction day 4 (D4), 8 (D8) and 12 (D12), 
as well as MEF, ESC and iPSC, were subjected to RT-qPCR specifically detecting 
endogenous Kdm2b-IF1. The results were normalized to the expression of Gapdh and 
compared to MEF. n = 2. (B) Doxycyclin-inducible overexpression of Kdm2b introduced 
by lentivirus. RNA samples were harvested from ESC, MEF without transduction (−) and 
MEF transduced with lentiviral Kdm2b construct and treated with doxycyclin for 4 days 
(OE). The results of RT-qPCR detecting the open reading frame (ORF) of Kdm2b-IF1 
were normalized to the expression of Gapdh and compared to the expression level in ESC, 
which is set to 1. n = 2. 
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Figure S3-3 Overexpression of Kdm2b does not affect expression of retroviral 
reprogramming factors.  
RNA samples were harvested from MEF introduced with indicated factors. RT-qPCRs 
were performed using primers specifically detecting the transgenes. The results were 
normalized to Gapdh and compared to OSK or OSKM transduction. n = 2. 
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Figure S3-4 Kdm2b enhances transcription activation in the examined time 
window.  
Hierarchical clustering of all the probes representing upregulated and downregulated 
signature reprogramming genes based on their expression in OSK and Kdm2b-assisted 
OSK reprogramming. The signature genes were compiled from the previously published 
literature (Samavarchi-Tehrani et al. 2010) and denoted on the right side of the heat map. 
Kdm2b mainly affects the expression of upregulated genes in the initial phase in the 
examined time window from day 4 to day 12. The upregulated genes in the maturation 
and stabilization phase and the downregulated genes in the whole reprogramming process 
clustered together with mild or no alternation in gene expression. The extent of 
upregulation by Kdm2b from low (white) to high (orange) is also indicated by the vertical 
wedge with color gradient.  Overexpression of Kdm2b does not affect expression of 
retroviral reprogramming factors.  
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Figure S3-5 RT-qPCR showing the expression of mesenchymal genes and 
endogenous pluripotent genes in Kdm2b-assisted reprogramming.  
(A) Mesenchymal genes repressed in the maturation stage in reprogramming show mild 
to slight repression at the later time points in the Kdm2b-assisted reprogramming. (B) 
Endogenous loci of Oct4 and Sox2 do not show activation by Kdm2b in the examined 
time points. RNA samples for RT-qPCR in A and B were prepared as described in Figure 
3-6A. n = 2.  
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Table S3-1 Target sequences of shRNAs used in Chapter Three. 
Target Seed sequence Reference 
Kdm2b GCTCCAACTCAGTTACTGT 
(He et al. 
2008) 
Control (lacZ from E. coli) GTTCAGATGTGCGGCGAGT 
Ink4a/Arf GCGATATTTGCGTTCCGCT This study 
Cdh1 (i1) GGAGATGCAGAATAATTAT 
(Li et al. 
2010) 
Cdh1 (i2) GCTGGAATCTTTGTCCATGTA 
Cdh1 (i3) GCAGGAAGAGAACATTCTA 
 
  
                                                                                                                            
92 
 
Table S3-2 Sequences of primers used in quantitative and semi-quantitative RT-
PCR in Chapter Three. 
Quantitative RT-PCR 
Target Direction Sequence 
Arf 
F GCCGCACCGGAATCCT 
R TTGAGCAGAAGAGCTGCTACGT 
Cdh1 
F AACAACTGCATGAAGGCGGGAATC 
R CCTGTGCAGCTGGCTCAAATCAAA 
Crb3 
F CCGGACCCTTTCACAAATAG 
R TCGCATGAGCAGAAACAGTC 
Dsp 
F GCGGCTTGGGTGGGAGTGTC 
R GGCCGCAATGGGGCTTGACT 
Dsg 
F AAGGCCACGCCCATTCCCATCA 
R TTTCCAATCGACCTGCTGAGGCT 
Gapdh 
F CATGGCCTTCCGTGTTCCTA 
R GCCTGCTTCACCACCTTCTT 
Ink4a 
F CGTACCCCGATTCAGGTGAT 
R TTGAGCAGAAGAGCTGCTACGT 
Ink4b 
F ATGTTGGGCGGCAGCAGTGACG 
R ATCTCCAGTGGCAGCGTGCAG 
Insm1 
F TGCGTCCGGCCTGCTAGAGT 
R GCTCCACCGAAGCGAAGCGA 
Irf6 
F GCACCTGCTCCTGAGCACGG 
R GCCGCGTGGCATGTTTCCAG 
Kdm2a 
F AGGAAGGCATCCCTGGAGTGGTT 
R AGCGACGACGCATGGTACCACG 
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Kdm2b-IF1 (en) 
F ATGCAGGGGGCAGGAGTGTTGA 
R CTGAAGCCACGGACGCTGACAA 
Kdm2b-IF1 (ORF) 
F TGGAGGCAGAGAAAGACTCTGGAAG 
R CCAGGCTGAAGCCACGGACG 
Kdm2b-IF2 
F GGCGCTGCTCCAGCCATGTCAG 
R CGAGCTCCTGCTGTTGTTCGGTT 
Kdm2b-IF3 
F CGCTCGTGGGGAGATGAGGCAG 
R GCCACGGACGCTGACAATTTCCT 
Nanog 
F AAGCAGAAGATGCGGACTGT 
R ATCTGCTGGAGGCTGAGGTA 
Ocln 
F CCTCCAATGGCAAAGTGAATGGCA 
R TGTTTCATAGTGGTCAGGGTCCGT 
Oct4 (en) 
F TAGGTGAGCCGTCTTTCCAC 
R CCTTGGAAGCTTAGCCAGGT 
pMXs-Klf4 
F TCCCAGTGTGGTGGTACGGGA 
R AGTTGCTTTCCACTCGTGCT 
pMXs-Myc 
F GCCACCGCCTACATCCTGTCC 
R GACCGGCGCTCAGCTGGAAT 
pMXs-Oct4 
F (As pMXs-Klf4 F) 
R AGTTGCTTTCCACTCGTGCT 
pMXs-Sox2 
F CTGCCCCTGTCGCACATGTG 
R CTTTTATTTTATCGTCGACC 
Snai1 
F TTGTGTCTGCACGACCTGTGGAAA 
R TCTTCACATCCGAGTGGGTTTGGA 
Snai2 
F CACATTCGAACCCACACATTGCCT 
R TGTGCCCTCAGGTTTGATCTGTCT 
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Sox2 (en) 
F TGATCAGCATGTACCTCCCC 
R CCCTCCCAATTCCCTTGTAT 
Tdgf1 
F CGGAGATCTTGGCTGCTAAC 
R CTTCGACGGCTCGTAAAAAC 
Zeb1 
F TGCTCACCTGCCCGTATTGTGATA 
R AGTGCACTTGAACTTGCGGTTTCC 
Zeb2 
F TGATAGCCTTGCAAACCCTCTGGA 
R ATTGTGGTCTGGATCGTGGCTTCT 
Semi-quantitative RT-PCR   
Target Direction Sequence 
pMXs-Klf4 
F CCAAAGAGGGGAAGAAGGTC 
R CCTACAGGTGGGGTCTTTCA 
pMXs-Oct4 
F CCAGAAGGGCAAAAGATCAA 
R (As pMXs-Klf4 R) 
pMXs-Sox2 
F ACCAGCTCGCAGACCTACAT 
R (As pMXs-Klf4 R) 
pTYF-TRE-Kdm2b 
F CCCGAGACTCGCTGACAG 
R GGCTAAGATCTACAGCTGCC 
Gapdh 
F CATGGCCTTCCGTGTTCCTA 
R GCCTGCTTCACCACCTTCTT 
 
F, forward primers; R, reverse primers; en, endogenous loci; ORF, open reading frame   
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Table S3-3 Sequences of primers used in ChIP-qPCR in Chapter Three. 
Target locus Amplicon location Direction Sequence 
Cdh1 
A: −5,504 ~ −5,383 
F GGGGCTACCAACCGCAAGGTG 
R AGGCCGGCCCCTTCCCATAG 
B: −1,935 ~ −1,770 
F AGGCACAGCCTCCACACCTCA 
R AGCCACCCTCCTCAGCGACA 
C: −646 ~ −563 
F CCCCACTTGTGCAATCCCAGCA 
R CCAACTCAGGTGGGCCTGGA 
D: −10 ~ 66 
F TGCGCTGCTCACTGGTGTGG 
R AGGCCGGGCAGGAGTCTAGC 
E: 415 ~ 505 
F CCGGGTTGAGCAGGGTCCCT 
R CCGCGCTACTTCAGCACCCC 
F: 16,297 ~ 16,377 
F AGCTGTCGGAGCCTCAGGGG 
R TGTGGCCCTCCCCTCTCAGC 
G: 50,234 ~ 50,315 
F TCAGCTGCCCCGAAAATGA 
R GGGCAGAGCCTGCCACCAAC 
Dsg2 −287 ~ −188 
F CGCTTGGCCAGCGTGTCTCC 
R GCGCGACTCATGGAGCCTGG 
Dsp −251 ~ −172 
F TCCGCCTCTTGGGGGAGTAGG 
R GACCCCGCGGGACTTGCTTC 
Epcam −217 ~ −70 
F GGGCCTGCTTTTTCTCCCGCC 
R GCCCCCAGTTTGGGTTGGTCAG 
Irf6 −383 ~ −226 
F TAGAACACGGGGTCCACGGGC 
R GAGCGTCGCCCCTCCCGTA 
Nanog −180 ~ −134 
F TCCCTCCCTCCCAGTCTG 
R CCTCCTACCCTACCCACCC 
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